Pathogenic mediators in multiple sclerosis: GM-CSF and other TH cell-derived cytokines by Jerg Hartmann, Felix








Pathogenic mediators in multiple sclerosis: GM-CSF and other TH
cell-derived cytokines
Jerg Hartmann, Felix





Jerg Hartmann, Felix. Pathogenic mediators in multiple sclerosis: GM-CSF and other TH cell-derived
cytokines. 2016, University of Zurich, Faculty of Science.
   
 
Pathogenic Mediators in Multiple Sclerosis:  





Erlangung der naturwissenschaftlichen Doktorwürde 

















Prof. Dr. Burkhard Becher  
(Vorsitz und Leitung der Dissertation) 
Prof. Dr. Christian Münz 











The thesis was based upon and partly adapted from the following publications: 
 
 
Multiple sclerosis-associated IL2RA polymorphism controls GM-CSF production 
in human TH cells  
Felix J. Hartmann, Mohsen Khademi, Jehan Aram, Sandra Ammann, Ingrid 
Kockum, Cris Constantinescu, Bruno Gran, Fredrik Piehl, Tomas Olsson, Laura 
Codarri & Burkhard Becher 
 
The End of Gating? An introduction to automated analysis of high dimensional 
cytometry data 
Florian Mair*, Felix J. Hartmann*, Dunja Mrdjen, Vinko Tosevski, Carsten Krieg 
and Burkhard Becher. *Contributed equally 
 
 
And partially from the following manuscripts in preparation: 
 
 
High-Dimensional Mass Cytometry for Extensive Profiling of Pathogenic 
Mediators in Multiple Sclerosis (working title) 
Felix J. Hartmann, Dunja Mrdjen, Edoardo Galli, Lukas Weber, Mark Robinson, 
Mohsen Khademi, Carsten Krieg, Fredrik Piehl, Tomas Olsson and Burkhard Becher 
 
Immune-Activation in Narcolepsy Revealed by High-Dimensional Mass 
Cytometry (working title) 
Felix J. Hartmann, Raphael Bernard-Valnet, Dunja Mrdjen, Edoardo Galli, Lukas 








Table of Contents 
DISCLAIMER ............................................................................................................. I 
TABLE OF CONTENTS ......................................................................................... III 
ZUSAMMENFASSUNG ......................................................................................... VII 
SUMMARY ............................................................................................................ VIII 
ABBREVIATIONS ................................................................................................... IX 
1. INTRODUCTION ............................................................................................... 1 
1.1. CLINICAL FEATURES OF MULTIPLE SCLEROSIS ...................................................... 1 
1.1.1. Diagnosis and clinical course ...................................................................... 2 
1.1.2. Treatment ..................................................................................................... 3 
1.2. RISK FACTORS OF MULTIPLE SCLEROSIS ............................................................... 4 
1.2.1. Genetic risk factors ...................................................................................... 4 
1.2.2. Environmental risk factors ........................................................................... 6 
1.3. THE IMMUNE SYSTEM IN MULTIPLE SCLEROSIS ..................................................... 7 
1.3.1. Helper T cells ............................................................................................... 7 
1.3.2. Cytotoxic T cells ........................................................................................... 9 
1.3.3. gd T cells ...................................................................................................... 9 
1.3.4. B cells ........................................................................................................... 9 
1.3.5. Mononuclear phagocytes ........................................................................... 10 
1.3.6. Other innate immune cells ......................................................................... 10 
1.4. GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR ......................... 11 
1.4.1. The biology of GM-CSF ............................................................................. 11 
1.4.2. Cellular sources of GM-CSF ..................................................................... 11 
1.4.3. GM-CSF receptor signaling ...................................................................... 12 
1.4.4. Cellular targets and effects of GM-CSF .................................................... 12 
1.4.5. GM-CSF in autoimmune neuroinflammation ............................................ 13 
1.4.6. GM-CSF in rheumatic and other autoimmune diseases ............................ 14 
1.5. EMERGING CYTOMETRY TECHNOLOGIES ............................................................ 15 
1.5.1. History developments in flow cytometry .................................................... 15 
1.5.2. The principle of mass cytometry ................................................................ 15 
 
 iv 
1.6. ANALYSIS OF HIGH-DIMENSIONAL CYTOMETRY DATA ....................................... 18 
1.6.1. Limitations of manual data analysis .......................................................... 18 
1.6.2. Setting the stage for alternatives ................................................................ 18 
1.6.3. Bioconductor and R provide a versatile analysis platform ....................... 19 
1.6.4. Principle component analysis .................................................................... 19 
1.6.5. Recently developed algorithms for automated data analysis .................... 20 
1.6.6. Practical considerations for automated data analysis .............................. 28 
2. AIMS OF THE STUDY .................................................................................... 30 
2.1. PART I – ESTABLISHING THE ROLE OF GM-CSF IN MS ...................................... 30 
2.2. PART II – HIGH-DIMENSIONAL ANALYSIS OF TH CELL POLARIZATION IN MS ..... 30 
3. RESULTS – PART I .......................................................................................... 31 
3.1. REGULATION OF GM-CSF PRODUCTION IN HUMAN TH CELLS ............................ 31 
3.1.1. IL-2 induces the production of GM-CSF ................................................... 31 
3.1.2. IL-2Ra engagement drives GM-CSF in human TH cells ............................ 33 
3.1.3. IL-2 drives GM-CSF production independent of proliferation .................. 34 
3.1.4. GM-CSF expression is regulated via STAT5 ............................................. 35 
3.2. THE INFLUENCE OF REGULATORY T CELLS ......................................................... 36 
3.2.1. Treg cells inhibit GM-CSF
+
 TH cells through IL-2 deprivation .................. 36 
3.3. GM-CSF EXPRESSION IN MULTIPLE SCLEROSIS .................................................. 37 
3.3.1. GM-CSF secreting TH cells are elevated in MS patients ........................... 37 
3.3.2. GM-CSF
+
 TH cells coincide with biomarkers for disease severity ............ 40 
3.4. GENETIC MODULATION OF GM-CSF PRODUCTION ............................................. 40 
3.4.1. IL2RA risk alleles convey an elevated frequency of GM-CSF
+
 TH cells ... 40 
3.4.2. IL2RA-influence on GM-CSF is preserved upon IL-2R engagement ........ 42 
3.5. GM-CSF EXPRESSION BY CYTOTOXIC T CELLS .................................................. 43 
4. RESULTS – PART II ........................................................................................ 44 
4.1. ESTABLISHING A MASS CYTOMETRY WORKFLOW ............................................... 44 
4.1.1. Design of the metal-metal isotope labeled antibody panel ........................ 44 
4.1.2. Establishing live cell barcoding ................................................................. 47 
4.2. HIGH-DIMENSIONAL ANALYSIS OF IMMUNE POPULATIONS IN MS PATIENTS ....... 47 
4.2.1. Algorithm-guided definition of immune lineages ....................................... 47 
4.2.2. Defined cytokine-producing TH cell populations expand in MS ................ 49 
4.2.3. Cytotoxic T cells in MS .............................................................................. 52 
 
 v 
4.2.4. B cells and NK cells in MS ......................................................................... 53 
5. DISCUSSION ..................................................................................................... 56 
5.1. THE ROLE OF GM-CSF IN MS AND OTHER AUTOIMMUNE DISEASES .................. 56 
5.2. THE REGULATION OF GM-CSF BY IL-2 SIGNALING ........................................... 56 
5.3. THE GENETIC INFLUENCE ON GM-CSF PRODUCTION ......................................... 57 
5.4. MASS CYTOMETRY FOR THE IN-DEPTH ANALYSIS OF CLINICAL PHENOTYPES ..... 57 
5.5. ALGORITHM-GUIDED DATA ANALYSIS ................................................................ 58 
5.6. GM-CSF PRODUCING TH CELLS COMPRISE SEVERAL SUBSETS ........................... 59 
5.7. MODULATION OF FURTHER IMMUNE POPULATIONS IN MS ................................. 59 
5.8. CONCLUSIONS .................................................................................................... 60 
6. METHODS ......................................................................................................... 61 
6.1. HEALTHY DONOR AND PATIENT SAMPLES FOR GM-CSF STUDIES ...................... 61 
6.1.1. Human PBMC samples .............................................................................. 61 
6.1.2. Characterization of patient cohorts ........................................................... 61 
6.1.3. Characterization of healthy donors ........................................................... 63 
6.2. PBMC ISOLATION, CRYOPRESERVATION AND THAWING .................................... 63 
6.3. IN VITRO CULTURE .............................................................................................. 63 
6.3.1. Regulation of GM-CSF production ............................................................ 63 
6.3.2. Impact of regulatory T cells ....................................................................... 64 
6.4. EX VIVO RESTIMULATION OF PBMCS ................................................................. 64 
6.5. FLOW CYTOMETRY ............................................................................................ 64 
6.5.1. Flow cytometry and cell sorting ................................................................ 64 
6.5.2. Intracellular cytokine staining ................................................................... 65 
6.5.3. STAT5 phosphorylation and Ki-67 staining .............................................. 65 
6.5.4. Acquisition and analysis ............................................................................ 65 
6.6. QUANTITATIVE REAL-TIME PCR ....................................................................... 65 
6.7. MICROSCOPY ..................................................................................................... 66 
6.8. ELISA ............................................................................................................... 66 
6.9. STATISTICAL ANALYSIS ...................................................................................... 66 
6.10. HEALTHY DONOR AND PATIENT SAMPLES FOR MASS CYTOMETRY STUDIES ...... 67 
6.10.1. Recruitment of patients ............................................................................ 67 
6.11. MASS CYTOMETRY ........................................................................................... 67 
6.11.1. Antibody conjugation and validation ....................................................... 67 
 
 vi 
6.11.2. Live cell barcoding .................................................................................. 68 
6.11.3. Surface staining for mass cytometry ........................................................ 68 
6.11.4. Intracellular cytokine staining for mass cytometry ................................. 70 
6.11.5. Acquisition on CyTOF2 mass cytometer and bead normalization .......... 70 
6.12. ALGORITHM-GUIDED DATA ANALYSIS .............................................................. 70 
6.12.1. Data pre-processing ................................................................................. 70 
6.12.2. FlowSOM clustering ................................................................................ 71 
6.12.3. t-SNE dimensionality reduction ............................................................... 72 
6.12.4. Statistical analysis of mass cytometry experiments ................................. 72 
REFERENCES ........................................................................................................... 73 
ACKNOWLEDGEMENTS ...................................................................................... 86 







Autoimmunerkrankungen wie Multiple Sklerose (MS) entstehen durch eine 
deregulierte Immunantwort, bei der Gewebe des eigenen Körpers durch eine 
Abwehrreaktion angegriffen werden. Im Falle der MS ist das zentrale Nervensystem 
betroffen was zu einer Vielfalt an neurologischen Symptomen führt. Zur 
Immunreaktion in MS tragen vielerlei verschiedene Zelltypen bei, wobei sogenannte 
T-Helfer Zellen eine zentrale Rolle spielen. T-Helfer Zellen schütten eine Reihe 
unterschiedlicher Substanzen aus, sogenannte Botenstoffe oder Zytokine, um mit 
anderen Zellen zu kommunizieren und so die Immunantwort zu koordinieren. Durch 
Forschung im Mausmodell der Multiplen Sklerose konnte gezeigt werden, dass 
besonders ein Zytokin namens „Granulocyte Macrophage-Colony Stimulating Factor“ 
(GM-CSF) einen essentiellen Beitrag in der Entstehung dieser Autoimmunerkrankung 
übernimmt. 
In der hier vorliegenden Arbeit konnten wir zeigen, dass T-Helfer Zellen in Multiple 
Sklerose Patienten vermehrt GM-CSF ausschütten und dass dies mit einem 
verschlechtertem Krankheitsverlauf einhergeht. Die Produktion von GM-CSF in T-
Helfer Zellen wird hauptsächlich durch das Zytokin Interleukin-2 angeregt. Des 
weiteren zeigt diese Arbeit, dass eine Genvariante im Rezeptor für Interleukin-2 zu 
einer gesteigerten GM-CSF Produktion führt. Diese Erkenntnis stellt somit einen 
möglichen molekularen Mechanismus dar, wie diese genetische Variante das Risiko 
an Multipler Sklerose zu erkranken erhöht. 
Im weiteren Verlauf dieser Arbeit wurde die Zytokin-Produktion der T-Helfer Zellen 
von MS Patienten anhand der neu entwickelten Methode der sogenannten Massen-
Zytometrie in einer zuvor unerreichten Dimensionalität untersucht. Dadurch konnten 
wir einerseits die erhöhte GM-CSF Produktion in MS Patienten bestätigen und 
zusätzlich eine spezifische Charakterisierung dieser T-Helfer Zellen erstellen. GM-
CSF-produzierende T-Helfen Zellen lassen sich in mehrere Subtypen unterteilen, von 
denen eine spezifische Gruppe, nicht aber die anderen, in MS Patienten erhöht sind. 
Zusammengefasst sollen diese Erkenntnisse somit zu einem verbesserten Verständnis 
der Entstehung der Multiplen Sklerose, sowie möglicherweise zu neuen 





Autoimmune diseases such as multiple sclerosis (MS) are a result of dysregulated 
immune mechanisms, leading to the destruction of tissues by the immune system. In 
the case of MS, the targeted organ is the central nervous system, which leads to the 
establishment of a heterogeneous set of neurological symptoms in the patients. 
Multiple lineages of immune cells are involved in this process and especially T-helper  
(TH) cells have been shown to play a crucial role. TH cells are able to direct immune 
responses and communicate with other cell types via soluble mediators, termed 
cytokines. Research using an animal model of MS has shown that the initiation of 
neuro-inflammation is dependent on the TH cell-derived cytokine “granulocyte 
macrophage-colony stimulating factor“ (GM-CSF).  
In this thesis, we report an increased frequency of GM-CSF-producing by TH cells in 
MS patients. This elevated GM-CSF production was associated with several 
biomarkers of disease activity and severity. Further, we found that GM-CSF secretion 
in human TH cells is strongly induced by interleukin 2. Additionally, we here show 
that an MS-associated genetic polymorphism in the interleukin 2 receptor gene 
specifically increases the frequency of GM-CSF producing TH cells, thus proposing a 
possible molecular mechanism of how an immunologically relevant genetic risk 
factor might translate into an increased risk of multiple sclerosis. 
Extending these studies, we employed the recently developed mass cytometry 
technology to further analyze TH cell cytokine production in MS patients with a 
unprecedented high-dimensionality. Firstly, we could validate the increased GM-CSF 
production in MS patients and further, we were able to perform an in-depth 
description of these cells. This characterization revealed that GM-CSF producing TH 
cell can be divided into several subsets which have been associated with distinct TH 
cell lineages. Moreover, we could show that only specific subtypes of these GM-CSF 
producing TH cells are elevated in MS patients, thus further refining our 
understanding of the role of this cytokine in MS. 
Together, we hope that these results will add to our knowledge of TH cell biology in 
general and especially to our understanding of the pathogenic role of these cells in 
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1.1. Clinical features of multiple sclerosis 
First described almost 180 years ago (Carswell 1838), multiple sclerosis (MS) is one 
of today’s most prevalent autoimmune diseases, affecting almost 10’000 patients in 
Switzerland (Pugliatti et al. 2006) and about 2.5 million worldwide. MS is a chronic 
inflammatory disorder of the central nervous system (CNS) i.e. the brain and spinal 
cord. A hallmark of MS are so called lesions or plaques which are found in the white 
and grey matter of the CNS and which represent areas of demyelination and loss of 
oligodendrocytes (Figure 1). These lesions are caused by immune infiltration and 
inflammation, resulting in demyelination, gliosis and ultimately neuroaxonal 
degeneration (Dendrou et al. 2015). 
 
 
Figure 1. Pathological lesions in the CNS are a hallmark of MS. Multiple sclerosis pathology is characterized 
by confluent demyelinated areas in the white and grey matter of the brain and spinal cord that are called plaques or 
lesions and that indicate a loss of myelin sheaths and oligodendrocytes. Figure and legend adapted from (Dendrou 
et al. 2015). 
 
MS presents with a heterogeneous set of clinical features. Frequently observed signs 
are cognitive impairments like attention deficits, fatigue, visual disturbances such as 
reduced color vision and acuity as well as affection of motor functions manifesting as 
poor balance, limb incoordination or spasms (Compston and Coles 2008). 
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1.1.1. Diagnosis and clinical course 
The common age of onset for MS is usually around 30 years (McFarlin and 
McFarland 1982a; McFarlin and McFarland 1982b). The majority of patients present 
in the clinics with a first acute episode known as the clinically isolated syndrome 
(CIS; Figure 2). The diagnosis of MS is mostly based on the presented neurological 
symptoms, however magnetic resonance imaging (MRI) can provide further evidence 
by detecting the dissemination of white matter lesions in space and time. 
Additionally, about 90% of MS patients show presence of oligoclonal bands after 




Figure 2. Heterogeneity of multiple sclerosis. Shown are the progression of disability over time for different 
forms of MS. Figure and legend adapted from (Dendrou et al. 2015).  
 
Following the initial acute episode, most patients (circa 85%) develop a relapse-
remitting form of the disease (relapse-remitting MS; RRMS) in which relapses occur 
erratically and are followed by a period of clinical recovery. However, with time the 
improvements from these relapses remains incomplete and symptoms accumulate 
(Figure 2). Eventually, the majority of patients transition to secondary progressive MS 
(SPMS) which represents a stage of the disease with a more steady progression and 
less pronounced or no relapses as compared to RRMS. About 10-15% of patients with 
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MS experience no distinct relapses and instead present with a gradually increasing 
neurological disability directly from the onset of the disease, thus termed primary-
progressive MS (PPMS) (Miller and Leary 2007).  
 
1.1.2. Treatment 
Currently approved MS therapeutics mostly are mostly aimed at reducing immune 
activation and infiltration into the CNS. Early drugs such as interferon-b (Ebers 
1998), glatiramer acetate (Comi et al. 2001) and the more recently approved dimethyl 
fumarate (Fox et al. 2012) are general immunomodulators with unclear mechanisms 
of action. Glucocorticoids have general anti-inflammatory and immunosuppressive 
properties and are thus used to treat acute attacks. Two other approved therapeutics, 
mitoxantrone (Hartung et al.) and teriflunomide (O’Connor et al. 2011) interfere with 
DNA synthesis and thus probably limit T cell proliferation. Acting more specific, 
natalizumab is an approved mAb directed against the integrin VLA4 (Polman et al. 
2006). It effectively inhibits T cell infiltration into the CNS (>65% reduction of 
relapses and >90% reduction of new inflammatory lesions) but bears the risk of 
opportunistic John Cunningham (JC) virus reactivation which leads to potentially life-
threatening progressive multifocal leukoencephalopathy (PML) (Bloomgren et al. 
2012). Fingolimod (Cohen et al. 2010), a functional antagonist of the sphingosine 1-
phospate (S1P) receptor inhibits  lymphocyte egress from the lymph nodes. Recently, 
a humanized monoclonal a-CD52 antibody (termed alemtuzumab) has been approved 
for MS therapy (Cohen et al. 2012). Alemtuzumab depletes T as well as B cells and is 
highly effective in suppressing MS inflammatory activity. To date, there are however 
no effective drugs for the treatment of SPMS or PPMS.  
Taken together, the newly approved therapies have a good efficacy, however they are 
often accompanied by side effect such as PML or other flu like infections. Thus 




1.2. Risk factors of multiple sclerosis 
1.2.1. Genetic risk factors 
MS is a multifactorial disease triggered by environmental factors in individuals with 
genetic predisposition. For example the substantially increased risk among relatives 
and the concordance rate of 30% between identical twins indicate that genetic factors 
strongly influence the disease susceptibility (Oksenberg et al. 2008). Recent genome 
wide association studies (GWAS) have identified around 110 distinct genetic regions 
to be reliably associated with multiple sclerosis (Figure 3a) (Hafler et al. 2007; 
Sawcer et al. 2011; Beecham et al. 2013). Together, genetic variation accounts for 
approximately 30% of the total disease risk (Beecham et al. 2013). 
 
 
Figure 3. Genetic risk factors for multiple sclerosis. a) Discovery phase results. Circos plot showing primary 
association analysis of 161,311 autosomal variants in the discovery phase (14,498 cases and 24,091 healthy 
controls). The outermost track shows the numbered autosomal chromosomes. The second track indicates the gene 
closest to the most associated SNP meeting all replication criteria. The third track indicates the physical position of 
the 184 fine-mapping intervals (green). The innermost track indicates −log(P) (two-sided) for each SNP (scaled 
from 0–12, which truncates the signal in several regions; Additionally, contour lines are given at the a priori 
discovery (−log(P) = 4) and genome-wide significance  (−log(P) = 7.3) thresholds. Orange indicates −log(P) ≥ 4 
and <7.3, and red indicates −log(P) ≥ 7.3. b) Graphic representation of the TH-cell differentiation pathway. 
Colored nodes are those containing a gene implicated by proximity to an SNP showing evidence of association. 
Red, strong evidence; orange discovery P value < 1 x 10
-4.5
; yellow discovery P value < 1 x 10
-3
. Figure and legend 
adapted from a) (Beecham et al. 2013) and b) (Sawcer et al. 2011).  
 
The majority of MS-associated genetic variants are found within immunologically 
relevant regions. Particularly single-nucleotide polymorphisms (SNPs) in genes 
involved in TH cell activation and maturation are over-represented in MS (Figure 3), 
thus specifically implicating the differentiation and polarization of TH cells in MS 




As for other autoimmune diseases, the strongest genetic associations found for MS lie 
within the major histocompatibility complex (MHC; histocompatibility leukocyte 
antigen (HLA) in humans). The contribution of the HLA associations are thought to 
account for 10%–60% of the genetic risk of MS (Haines et al. 1998). More 
specifically, the strongest risk factors are found within class II risk genes, especially 
HLA-DRB1*15:01. This contribution has been observed in many different 
populations and increases risk for RRMS  as well as PPMS (Oksenberg et al. 2008). 
Risk of MS is increased approximately threefold for heterozygote and sixfold for 
homozygote carriers (Sadovnick 2012). Weaker contributions stem from HLA-
DRB1*03:01 and HLA-DRB1*13:01 as well as some class I alleles (Moutsianas et al. 
2015). How these HLA genes confer risk for MS on a mechanistical level remains 
elusive.  
 
1.2.1.2. Interleukin 2 receptor alpha (IL2RA) 
Besides the HLA region, polymorphisms in the IL2RA are the most strongly 
associated factors in MS (Figure 3, p.4). IL-2 is a 15-kDa cytokine with pleiotropic 
functions in promoting TH cell differentiation and effector responses, as well as 
mediating immune tolerance via regulatory T (Treg) cells. IL-2 can bind either to its 
high-affinity receptor, which is composed of three subunits, IL-2Rα (CD25), IL-2Rβ 
(CD122) and the common γ-chain (γc or CD132), or to the intermediate affinity 
receptor consisting of the heterodimer of the IL-2Rβ and γc (Rochman et al. 2009). 
Importantly, IL-2 signaling has been explored a potential target for MS therapy. 
Attenuation of IL-2 receptor signaling by monoclonal antibodies against the IL-2Rα 
(daclizumab) was shown to be effective by reducing annualized relapse rate and the 
number of gadolinium-enhanced lesions and ameliorating clinical symptoms in 
clinical trials for MS (Bielekova et al. 2004; Rose 2012; Wiendl and Gross 2013; 
Pfender and Martin 2014). 
Polymorphisms in the IL2RA and especially one variant located in the first intron 
(rs2104286) have repeatedly been shown to be associated MS and also other 
autoimmune diseases such as rheumatoid arthritis (RA) and type 1 diabetes (T1D). 
For MS, the odds ratio has been reported to be around 1.2 (Hafler et al. 2007). A 
second polymorphism within the IL2RA (rs12722489) has been implicated previously 
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but dismissed by recent fine mapping studies (Beecham et al. 2013). Both SNPs have 
been previously shown to be associated with serum concentrations of soluble IL-2RA 
(sIL-2RA) (Maier et al. 2009b). However, the correlation was inconsistent with 
differential modifications of risk for different associated autoimmune diseases, thus 
most likely not providing a possible pathogenic mechanism for how this genetic 
variant increases risk of MS. 
 
1.2.2. Environmental risk factors 
Besides genetic factors, environmental, lifestyle and dietary factors have been 
identified as risk factors for MS (Ascherio et al. 2012). One specific risk factor is 
chronic infection with the Epstein-Barr virus (EBV), a human herpes virus. This 
infection is common and usually happens early in life without displaying major 
symptoms. When primary infection occurs later in life, it causes acute febrile illness, 
known as infectious mononucleosis. A history of infectious mononucleosis has been 
reported to increase the risk for MS approximately two- to threefold (Thacker et al. 
2006). It is however unknown whether these two phenomena might have a common 
origin, such as good hygiene in childhood, commonly referred to as the hygiene 
hypothesis (Bach 2002). The possible mechanisms which could link EBV infection 
and MS are still unknown, however multiple scenarios such as increased activation 
and survival of B and T cells or immortalization of B cells and autoantibody 
production have been proposed (Ascherio et al. 2012). Another environmental factor 
influencing MS risk is lack of sunlight exposure and thus lack of vitamin D 
production. Vitamin D in turn has been shown to posses multiple effects on various 
parts of the immune system, e.g. regulatory T cells (Ascherio and Munger 2007). 
Lastly, cigarette smoking increases MS risk approximately by 50%, directly 








1.3. The immune system in multiple sclerosis 
MS is strongly considered to be an autoimmune disease and various leukocyte 
populations have been shown to be involved in its pathogenesis. 
 
1.3.1. Helper T cells 
TH cells are at the center of the adaptive immune response. They recognize antigens 
presented on MHC class II molecules on the surface of professional antigen 
presenting cells (APCs). Once activated, they can execute multiple functions such as 
providing help to activate B cells to secrete antibodies (see 1.3.4), activating and 
maturing other myeloid cells to sustain the immune response (see 1.3.5) or assist in 
the activation of cytotoxic T cells to kill infected target cells (see 1.3.2). In order to 
perform this plethora of functions, naive TH cells undergo a functional diversification, 
which is usually dependent on the cytokine signals which they receive during their 
activation by APCs (O’Shea and Paul 2010). An overview of different proposed TH 
cell subsets and a simplified list of associated cytokines is shown in Figure 4.  
 
 
Figure 4. TH cell differentiation and cytokine production. The classical monolithic view: lineages and master 
regulators. Initial studies arising from in vitro cultured TH1 and TH2 cells led to the idea that these subsets behaved 
like lineages, meaning that their phenotype (i.e., selective cytokine production) was inflexible. Accordingly, these 
subsets expressed lineage-defining transcription factors that were sufficient to impart this selective cytokine 
production. As newer subsets of cytokine producing cells were identified, they too were viewed as stable lineages. 




Initially, TH cells were roughly distinguished into TH1 cells which in turn activate 
myeloid and cytotoxic T cells and TH2 cells which help stimulate B cells to produce a 
wide range of antibodies. These different lineages are defined by the pattern of the 
soluble cytokines which they produce. TH1 cells were found to express interferon 
gamma (IFN-γ), interleukin-2 (IL-2) and tumor necrosis factor-beta (TNF-β). On the 
other hand, TH2 cells were reported to express cytokines such as IL-4 and IL-13, but 
also IL-5, IL-6, IL-9 and IL-10 (Romagnani 2000). Subsequently, further TH cell 
subsets have been proposed. Induced regulatory T (iTREG) cells were found to express 
transforming growth factor beta (TGF-β) and IL-10 while TH17 cells were reported to 
produce IL-17A, IL-17F, IL-21 and IL-22 as well as GM-CSF. More recently, it has 
been shown that TH17 cells also express cytokines traditionally associated with other 
TH subsets, such as IFN-γ and IL-10 (Zielinski et al. 2012). Additionally, further 
subsets have been described: TH9 cells (Schmitt et al. 2014), expressing mainly IL-9 
as well as IL-10 and IL-21, and follicular T helper (TFH) cells (Crotty 2011) 
expressing IL-21, but also an array of cytokines associated with other TH cell subsets. 
Lastly, a subset of TH22 cells has been proposed, characterized by the expression of 
IL-22 and TNF-α (Eyerich et al. 2009). 
In MS, TH cell activation, differentiation and cytokine production are believed to be 
the key pathogenic mechanisms. Evidence for this includes the fact that transfer of 
CD4
+
 T cells from diseased mice is sufficient to initiate EAE in healthy recipient 
animals (Ben-Nun et al. 1981), the strong genetic connection with the MHC class II 
locus and other TH cell-associated genes (see 1.2.1) and the effectiveness of several T 
cell directed therapies (see 1.1.2). It is hypothesized that autoreactive TH cells become 
activated, either by molecular mimicry, bystander activation or the co-expression of T 
cell receptors (TCRs) with different specificities and then migrate to the CNS 
(Dendrou et al. 2015). The exact nature of the TH cell polarization pattern following 
activation in MS has been the focus of intense research for several decades (Becher 
and Segal 2011). Initially TH1 cells had been identified as potential pathogenic 
mediators, followed by TH17 cells. Surprisingly however, both signature cytokines 
IFN-γ and IL-17A are not essential for the development of neuroinflammation in 
animal models (Codarri et al. 2011).   
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1.3.2. Cytotoxic T cells 
Cytotoxic T cells are MHC class I restricted cells which protect against viruses or 
other intracellular pathogens by killing infected cells. Interestingly, CD8
+
 T-cells are 
abundantly found in human MS lesions (Booss et al. 1983) and thus believed to be 
involved in MS pathology (Salou et al. 2015). MHC class I alleles are also associated 
with MS, although to a lesser extent than MHC class II. The functional roles of CD8
+
 
T cells in MS remain controversial and research in animal models has mostly focused 
on CD4
+
 T cells. Several reports exist showing that similar to CD4
+
 T cells, myelin-
specific CD8
+
 T cells were also able to induce CNS autoimmunity in mice (Sun et al. 
2001; Huseby et al. 2001). However, CD8
+
 T cells might also exert regulatory 
functions in the context of multiple sclerosis as has been suggested by several studies 
(Sinha et al. 2015). 
 
1.3.3. gd T cells 
gd T cells are cells with features of both, the innate as well as the adaptive arm of the 
immune system. They are found in human blood to some extent, but in much higher 
frequencies in several other sites such as mucosal tissues or dermis where they 
produce cytokines that regulate pathogen clearance, inflammation and tissue 
homeostasis (Bonneville et al. 2010). gd T cells have been implicated in several 
autoimmune diseases, such as systemic lupus erythematosus  (SLE), RA (Su et al. 
2013) and also in models of psoriasis (Cai et al. 2011; Pantelyushin et al. 2012). In 
MS patients, gd T cells were also found in CNS lesions, however whether this has 
functional consequences for the disease development remains unclear (Blink and 
Miller 2009).  
 
1.3.4. B cells 
B cells represent the humoral arm of the adaptive immune system. Their main 
function is the production of antibodies which then specifically bind their antigen, 
thus either directly neutralizing pathogenic particles or indirectly facilitating the 
phagocytosis of microbes by other immune cells. Additionally, B cells can perform 
further effector functions such as antigen presentation and cytokine production. 
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Increasing evidence suggests that B cells also partake in MS pathogenesis. Their 
levels are elevated in both, the CNS and the CSF of MS patients (Cepok et al. 2001). 
Oligoclonal bands derived from CSF IgG are a hallmark of MS diagnosis and IgG is 
also frequently found in MS lesions (Lucchinetti et al. 2000). Additionally, highly B 
cells-enriched, germinal center-like structures have been observed in the meninges of 
RRMS and SPMS patients (Magliozzi et al. 2007). A critical functional role for B 
cells is also supported by clinical trials directly targeting B cells. Firstly, depletion of 
B cells using the anti-CD20 monoclonal antibody rituximab has shown significant 
clinical activity in MS patients (Hauser et al. 2008). Similarly, the follow-up a-CD20 
antibody ocrelizumab (Kappos et al. 2011) is currently being investigated in phase III 
trials, again showing substantial clinical efficacy.  
 
1.3.5. Mononuclear phagocytes 
The mononuclear-phagocyte system (MPS) comprises cells of the myeloid lineage, 
specifically macrophages, dendritic cells (DCs) and monocytes (Hume 2006; 
Guilliams et al. 2014). Collectively, they perform various functions such as tissue 
remodeling and homeostasis as well as antigen presentation and other stimulatory or 
regulatory immune influences (Yona and Jung 2010). Antigen-presentation is 
essential for the initial activation of TH cells in animal models of neuroinflammation 
and myeloid cells constitute a large fraction of CNS invading cells in EAE as well as 
in MS, suggesting local re-activation of infiltrating lymphocytes. Additionally, 
monocyte-derived cells were suggested to actively participate in demyelinative 
processes (Yamasaki et al. 2014). Neuronal function can also directly be impaired by 
reactive oxygen species (ROS) or other oxidative stress and mononuclear cells of MS 
patients have been shown to produce increased amounts of ROS (Vladimirova et al. 
1999).  
 
1.3.6. Other innate immune cells 
Neutrophils are an abundant type of granulocyte which quickly traffic to sites of 
infection where they perform antimicrobial functions and contribute to the activation 
of other immune cells. They have been shown to posses an activated phenotype in MS 
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(Naegele et al. 2012) and several neutrophil-related factors have been proposed as 
potential biomarkers in MS (Rumble et al. 2015). 
Natural killer (NK) cells are cells of the innate immune system which can release 
cytokines and perform cytotoxic functions such as killing of virally infected cells and 
tumor cells. Changes of NK cell functionality in MS were associated with MS 
activity, and depletion of NK cells exacerbated EAE (Zhang et al. 1997). 
Additionally, it has been reported that several MS therapies, such as interferon-b, 
glatiramer acetate, fingolimod, daclizumab, or mitoxantrone seem to affect NK cell 
functionality (Chanvillard et al. 2013). 
 
1.4. Granulocyte-macrophage colony stimulating factor 
1.4.1. The biology of GM-CSF 
Granulocyte-macrophage colony stimulating factor (GM-CSF) or CSF2 is a 
pleiotropic cytokine that belongs to the CSF family of growth factors. Secreted by 
different cell types, GM-CSF can affect a variety of cells such as hematopoietic 
progenitor cells and many innate immune populations (Wicks and Roberts 2015). It is 
part of the colony-stimulating factor (CSF) family of growth factors. Initially, it was 
described to induce in vitro differentiation of hematopoietic progenitor cells into 
colonies comprising granulocytes and macrophages. Mice deficient in the Csf2 gene 
develop normally apart from lacking alveolar macrophages (Guilliams et al. 2013), a 
reduction in the number of eosinophils (Becher et al. 2014) and reduced CD103 
expression by BATF3 dependent dendritic cells (Edelson et al. 2011). The lack of 
lung alveolar macrophages leads to surfactant deposition in the lungs, a phenotype 
which resembles human pulmonary alveolar proteinosis (PAP) and which has also 
been linked with GM-CSF specific autoantibodies (Sakagami et al. 2009). 
 
1.4.2. Cellular sources of GM-CSF 
GM-CSF can be produced by a wide array of different immune cells, among them 
most prominently T cells and B cells, but also non-hematopoietic cells such as 
endothelial and pulmonary epithelial cells (LeVine et al. 1999) or osteoblasts and 
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tumor cells. The factors driving the production of GM-CSF by T cells are not yet fully 
understood and reports have been contradictory. Early studies indicated that IL-2 or 
IL-1b could increase GM-CSF production by human T cells (Burdach et al. 1991; 
Kruger et al. 1996). Using murine T cells, two studies demonstrated that IL-23 might 
be able to induce GM-CSF (Codarri et al. 2011; El-Behi et al. 2011), whereas later 
reports indicate the involvement of STAT5-inducing cytokines such as IL-7 (Sheng et 
al. 2014) or STAT4 inducers like IL-12 (McWilliams et al. 2015). Additionally, the 
transcription factor basic helix–loop–helix (bHLH) 40 (Bhlhe40) has been proposed 
to regulate GM-CSF production by murine TH cells (Lin et al. 2014). 
 
1.4.3. GM-CSF receptor signaling 
GM-CSF binds to the heterodimeric GM-CSF receptor (GM-CSFR) which is mainly 
found on cells of the myeloid lineage and their progenitors. The GM-CSFR is 
comprised of a low affinity ligand-binding a-chain and a signal-transducing b-chain, 
which is shared with the receptors for IL-3 and IL-5 (together known as the b-chain 
family of cytokines). GM-CSF binding to its receptor induces signal transducer and 
activator of transcription 5 (STAT5) and STAT3 phosphorylation (Hercus et al. 
2013). Further downstream, activation of mitogen-activated protein kinases 
(MAPKs), phosphatidylinositol 3 kinase (PI3K)–Akt and NFκB can occur. 
 
1.4.4. Cellular targets and effects of GM-CSF 
As indicated above, GM-CSF acts on a variety of cells (Figure 5). Firstly, it has been 
shown to promote bone marrow production of neutrophils and eosinophils (Metcalf 
2008) as well as activation of neutrophils and induction of several neutrophil effector 
functions. Other prominent cell types sensing GM-CSF are monocytes and 
macrophages. Again, GM-CSF stimulates their production in the bone marrow and 
regulates functions of differentiated cells such as maturation, survival and 
proliferation (Hamilton 2008). In the context of autoimmune neuroinflammation, 
GM-CSF has been recently demonstrated to be critical in driving an inflammatory 
signature in monocytes (Croxford et al. 2015). GM-CSF has also been shown to 
stimulate phagocytosis, induce upregulation of MHC class II and pattern recognition 
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receptors (PPRs), stimulate antigen processing and presentation and promote cell 
adhesion and chemotaxis (Wicks and Roberts 2015). Furthermore, GM-CSF has been 
shown to control the homeostasis of non-lymphoid tissue DCs (Greter et al. 2012). 
Systemic administration of GM-CSF leads to the mobilization of monocytes and other 
myeloid populations from the bone marrow to the blood and also primes them for an 
increased in vitro response to other stimuli, such as LPS (Hamilton 2008).  
 
 
Figure 5. The main functions of GM-CSF in the steady state and during inflammation. In vitro, in addition to 
the different effects of GM-CSF on immature myeloid precursor cells, GM-CSF can promote the survival and 
activation of macrophages, neutrophils and eosinophils, as well as dendritic-cell maturation. Data from GM-CSF-
deficient indicate that in the steady state GM-CSF, although restricted in expression, is crucial for the maturation 
of alveolar macrophages and invariant natural killer T (iNKT) cells.. Upon systemic administration or when the 
levels of these CSFs are increased, for example during inflammation or in response to infection, the CSFs can 
mimic their in vitro effects but also mobilize myeloid populations and their precursors into the blood, as well as 
precursor populations from other lineages (not shown). Figure and legend modified from (Hamilton 2008). 
 
1.4.5. GM-CSF in autoimmune neuroinflammation 
GM-CSF has also been proposed to be an important cytokine in autoimmune 
neuroinflammation. Firstly, cerebrospinal fluid (CSF) levels of GM-CSF have been 
shown to be increased in MS patients (Carrieri et al. 1998). Critically, administration 
of recombinant human GM-CSF to MS patients worsened their symptoms and 
induced relapses (Openshaw et al. 2000). Investigating the role of GM-CSF in murine 
models of neuroinflammation, it was shown that animals deficient in the GM-CSF 
(Csf2) gene are resistant to experimental autoimmune encephalomyelitis (EAE) 
(McQualter et al. 2001). Subsequent reports demonstrated that it is GM-CSF 
production by T cells which is critical for the establishment of the disease (Marusic et 
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al. 2002; Ponomarev et al. 2007; Codarri et al. 2011; El-Behi et al. 2011). Treatment 
of mice with neutralizing antibodies against GM-CSF (a-GM-CSF) ameliorated the 
disease (McQualter et al. 2001) and protected against relapses (Codarri et al. 2011). 
Early-phase clinical trials with a-GM-CSF antibodies in MS patients showed first 
indications of potential therapeutic effects (Constantinescu et al. 2015). 
 
1.4.6. GM-CSF in rheumatic and other autoimmune diseases 
GM-CSF levels are increased in the synovial fluid and blood of rheumatoid arthritis 
(RA) patients (Fiehn et al. 1992) and administration of GM-CSF to RA patients 
worsened the symptoms (Hazenberg et al. 1989). Additionally, recent reports have 
shown an increased risk for RA with genetic variants of the CSF2 gene (Okada et al. 
2014). Mice deficient in the Csf2 gene are protected from collagen-induced arthritis 
(CIA) (Campbell et al. 1998) and antibodies against GM-CSF or its receptor have 
been shown to reduce disease symptoms in the preclinical model as well as in RA 
patients (Burmester et al. 2011; Burmester et al. 2013).  
Furthermore, GM-CSF has been implicated to play a critical role in the pathogenesis 
of myocarditis (Sonderegger et al. 2008), as well as interstitial lung disease, colitis 




1.5. Emerging cytometry technologies 
1.5.1. History developments in flow cytometry 
2015 marked the 50-year anniversary of the publication of the first cell sorter, a 
device that was able to separate cells in suspension based on their difference in 
volume (Fulwyler 1965) as well as the first cytometry-based cell analyzer 
(Kamentsky et al. 1965). Shortly after that, the first sorter that could discriminate cells 
based on fluorescence was developed (Gödhe 1968; Wilder and Cram 1977), and this 
seminal work marked the advent of flow cytometry as a widely used, single-cell 
analysis technique driving the identification of all major immune cell subsets known 
today (Wilder and Cram 1977; De Rosa et al. 2001). These days, many laboratories 
are equipped with flow cytometers capable of detecting 10-20 parameters (Perfetto et 
al. 2004), revealing an ever-increasing diversity within established cellular subsets. 
However, traditional flow cytometry is based on fluorochromes and thus limited in 
the number of antigens to be investigated simultaneously by spectral overlap. To 
address this issue, an alternative cytometry-based technique has been recently 
developed and termed mass cytometry. 
 
1.5.2. The principle of mass cytometry 
Mass cytometry is based on the idea to couple the single-cell analysis approach of 
traditional flow cytometry with a mass spectrometric detection system (Bandura et al. 
2009; Bendall et al. 2012; Tanner et al. 2013). The general principle of mass 
cytometry and a typical workflow are outlined in Figure 6. Employing a mass 
spectroscopy as a quantification system thus eliminates problems in fluorescence-
based cytometry which are associated with spectral overlap. With mass cytometry, it 
is thus possible to simultaneously measure the expression level of approximately 50 
proteins on a single cell. Future developments in the available probes would allow 




Figure 6. Mass cytometry allows single-cell atomic mass spectrometry of heavy elemental (>100 Da) 
reporters. Schematic of ICP-MS-based analysis of cellular markers. An affinity product (e.g. antibody) tagged 
with a specific element binds to the cellular epitope. The cell is introduced into the ICP by droplet nebulization. 
Each cell is atomized, ionized, overly abundant ions removed, and the elemental composition of remaining heavy 
elements (reporters) is determined. Signals corresponding to each elemental tag are then correlated with the 
presence of the respective marker and analyzed using conventional cytometry platforms. Figure and legend taken 
from (Bendall et al. 2012). 
 
1.5.2.1. Heavy-metal tagged antibodies 
In analogy to flourescence cytometry, which mostly uses fluorescently labeled 
antibodies as probes, mass cytometry probes are commonly antibodies tagged with 
rare earth metals (Baranov et al. 2002) which are then quantified by time-of-flight 
(TOF) mass spectroscopy. These elements are stable, non-radioactive and usually not 
found in biological systems, thus giving virtually no biological background (Figure 
7). Tagging of the antibodies is achieved by complexing the desired ions in metal-
chelating polymers (Lou et al. 2007; Majonis et al. 2010). Prominent polymeric 
chelators at the moment are based on DTPA (diethylene triamine pentaacetic acid) 
and DOTA (1,4,7,10-tetraazacyclodode-cane-1,4,7,10-tetraacetic acid). Polymers can 
be attached to reduced disulfides in the Fc region of an antibody. Attaching 3-4 
polymers to one antibody, about 100 metal ions can be coupled to a single antibody 
(Ornatsky et al. 2010). The currently used polymers best chelate ions with a positive 
charge of three, however future developments of chelators for ions with a positive 






Figure 7. Heavy metal isotopes currently available for mass cytometry. The stable isotopes of these 24 
elements provide over 50 unique tags for use in mass cytometry. Figure and legend taken from Fluidigm. 
 
1.5.2.2. Mass spectrometric detection system 
Heavy-metal conjugated antibodies can then be used to stain the cells of interest 
following standard staining procedures. The stained cells are then injected into the 
mass cytometer where they reach a nebulizer creating single-cell droplets which, are 
then introduced into an inductively coupled plasma (ICP). This high-temperature ICP 
(up to 7000°K) vaporizes, atomizes and subsequently ionizes the cells (Bandura et al. 
2009). The resulting ion cloud is then filtered through a quadrupole which allows only 
heavy-metal ions to pass but blocks ions of biological elements commonly found in 
cells. Lastly, the ion cloud is quantified by a time-of-flight (TOF) mass analyzer and 
the data is stored in the flow cytometry standard (*.fcs) file format which is 





1.6. Analysis of high-dimensional cytometry data 
1.6.1. Limitations of manual data analysis 
While both fluorescence-based flow cytometry as well as mass cytometry provide a 
technological platform to interrogate the immune system at a previously 
unprecedented level (Bendall et al. 2012), scientific progress depends on our ability to 
analyze and comprehend the resulting data in a meaningful way. Historically, flow 
cytometric data was  - and still is - analyzed using a series of two-dimensional plots 
and manual gating, i.e. drawing regions of interest (gates) on a plot and either 
examining that subset on a different bivariate plot, or reporting a certain qualitative 
measure (cell subset is present or absent, or its relative proportion) or quantitative 
measure. While this approach is still adequate for many experimental settings, it 
suffers from several serious shortcomings. First, it is not easily scalable, as the 
number of two-dimensional plots increases exponentially with the number of 
measured parameters (i.e. an 18-parameter experiment would require a total of 153 
two-dimensional plots to display every marker combination) and thus cannot be easily 
comprehended anymore. Second, it has been shown by many multi-center studies, 
such as the Human Immune Genome Project, that manual gating is one of the largest 
variables in the outcome of a flow cytometry-based experiment (Maecker et al. 2012). 
Third, every manual gating approach relies on the researcher’s prior knowledge, thus 
introducing a bias towards “expected" results. Due to this focus, much of the 
potentially relevant and novel information within the dataset might not be recognized 
and could end up being ignored. 
 
1.6.2. Setting the stage for alternatives  
The above-mentioned problems were already recognized some years ago, and several 
independent groups have started to develop computational methods that automatically 
identify populations in multidimensional flow cytometry data. First reports on 
automated cytometry data analysis date back as early as 2007 (Quinn et al. 2007; Lo 
et al. 2008; Finak et al. 2009), and opened up the field for future developments. With 
the rapid increase of available tools, in 2010 the first FlowCAP (Flow Cytometry: 
critical assessment of population identification) challenge was initiated and revealed 
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that a large number of these automated algorithms perform equally well or even better 
than a human expert with respect to population identification as well as sample 
classification (Aghaeepour et al. 2013). The more recent FlowCAP challenges 
(http://flowcap.flowsite.org/) have seen a number of additional promising automated 
analysis approaches, among them several novel methods for clustering such as 
SWIFT (Naim et al. 2014) and immunoCLUST (Sörensen et al. 2015) (for an 
overview of available tools and their dedicated functions see references (Lugli et al. 
2010; Pedreira et al. 2013; Di Palma and Bodenmiller 2015; Kvistborg et al. 2015; 
Chester and Maecker 2015). 
 
1.6.3. Bioconductor and R provide a versatile analysis platform 
As the development of these tools is work in progress, the available packages often 
lack a user-friendly graphical user interface and instead require at least basic 
knowledge of one of the programming languages such as R, Python, Java or Matlab. 
Although possibly sounding like a barrier to any bench scientist, the use of tools 
written in these programming languages is facilitated by the existence of free, open 
source repositories containing well-documented and fully functional pieces of code 
(packages, add-ons, modules) that perform a particular task. Perhaps the best known 
open source repository is Bioconductor (www.bioconductor.org), a software 
repository originally developed for the analysis and comprehension of high-
throughput genomic data (Gentleman et al. 2004). It uses the statistical programming 
language R and currently contains 38 packages that deal with the various aspects of 
cytometry data handling. 
 
1.6.4. Principle component analysis 
Early work in analyzing high-dimensional cytometry data often deployed principal 
component analysis (PCA), a statistical method for reducing the dimensionality of 
complex datasets to two or three dimensions (Costa et al. 2010; Bendall et al. 2011; 
Newell et al. 2012). PCA takes all chosen parameters of the higher dimensional data 
and calculates a smaller number of variable parameters (called principal components) 
that best preserve most of the variability of the original data and can be more easily 
 
 20 
displayed (reviewed in (Genser et al. 2007)). However, PCA is a computational 
approach that assumes linear relationships between the measured parameters, which is 
not the case for many biological datasets. As a result, within the past years a variety 
of new algorithms have been developed which are based on non-linear dimensionality 
reduction (NLDR) and thus are adequate for the visualization and exploration of 
single-cell cytometry data. 
 
1.6.5. Recently developed algorithms for automated data analysis 
1.6.5.1. SPADE – building a tree of relationships 
One of the early tools used to computationally analyze and visualize high-dimensional 
mass cytometry data is Spanning-tree Progression Analysis of Density-normalized 
Events (SPADE) (Qiu et al. 2011). SPADE depicts cellular populations in a branched 
tree structure (dendrogram), thus visualizing high-dimensional data in an intuitive, 
two-dimensional manner (Figure 8). The SPADE tree consists of connected nodes 
that represent clusters of cells, thereby also providing information about the 
relationship of cell types. Typically, the branches of the resulting SPADE tree are 
manually annotated to give an immediate overview of the main cellular lineages. 
Further, a third dimension of color can be overlaid onto the tree to depict expression 
levels of any given marker or fold changes between multiple sample groups. Since the 
high-dimensional data is visualized as nodes that have undergone a clustering step, 
and therefore comprise multiple cells, the single-cell resolution of the data is lost at 
this point and any applied coloring represents subset characteristics. 
To create the SPADE tree, the algorithm follows a multi-step process. Briefly, 
SPADE first performs density-dependent down-sampling. Thus, cells with few similar 
neighbors in the high-dimensional space will be more likely to be included in the 
down-sampled dataset than cells with plenty of neighbor cells. This ensures a similar 
representation of rare and abundant cell types in the down-sampled dataset, and thus 
facilitates the identification of rare cellular subsets. Second, the algorithm performs 
hierarchical, agglomerative clustering, grouping cells with its closest neighbors until a 
user-defined number of clusters is reached. Next, SPADE constructs a minimum 
spanning tree by randomly choosing an already connected sub-graph and adding an 
edge to the cluster or sub-graph with the minimum distance to the selected sub-graph. 
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This process is iterated until all nodes are connected in one minimum spanning tree. 
Lastly, for all cells in the initial dataset SPADE determines the closest neighbor in the 
down-sampled data and assigns the cell to the corresponding cluster. 
 
 
Figure 8. Flowchart of SPADE and SPADE analysis of a simulated data set. (i) A simulated two-parameter 
flow cytometry data set, with one rare population and three abundant populations. (ii) Result of density- dependent 
down-sampling of the original data. (iii) Agglomerative clustering result of the down-sampled cells. Adjacent 
clusters are drawn in alternating colors. (iv) Minimum spanning tree that connects the cell clusters. (v) Colored 
SPADE trees. Nodes are colored by the median intensities of protein markers of cells in each node, allowing 
visualization of the behaviors of the two markers across the entire heterogeneous cell population. Figure and 
legend taken from (Qiu et al. 2011). 
 
The user-defined parameters that are required to construct the SPADE tree, in 
addition to the choice of cellular markers and the desired number of clusters, are the 
outlier density and target density. Outlier density is used to exclude cells with very 
few neighbor cells while the target density determines the outcome of the down-
sampling step and therefore modifies the threshold of rare populations that can still be 
identified. Since SPADE includes steps involving random decisions, it is of a non-
deterministic nature. As a consequence, several runs of SPADE will result in 
differently organized trees, which should be kept in mind when applying SPADE. 
While the organization of the tree at each individual run might appear distinct, the 
identified populations have been found to be comparable across several runs. SPADE 
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has been used in several publications (Bendall et al. 2011; Qiu et al. 2011; 
Bodenmiller et al. 2012; Lujan et al. 2015), mostly to give an instant overview of 
different immune populations and their expression of surface markers or intracellular 
signaling molecules. 
 
1.6.5.2. t-SNE – visualizing the similarity landscape 
Another powerful tool to visualize multi-parameter cytometry data is nonlinear 
dimensionality reduction via t-Stochastic Neighbor Embedding (t-SNE) (Maaten and 
Hinton 2008; Amir et al. 2013). t-SNE visualizes high-dimensional similarities of 
cells in an easily understandable two- or three-dimensional scatter plot, the so-called 
t-SNE map (Figure 9). The proximity of cells in the t-SNE map reflects their distances 
in the high-dimensional space. Cells that are similar in their analyzed protein-
expression pattern will be located closely together in the t-SNE map, thus enabling 
the visualization of different cellular subpopulations. Importantly, t-SNE has been 
shown to successfully identify small cellular subpopulations down to 0.25% (Amir et 
al. 2013) and is able to recognize high-dimensional associations of markers which 
might be missed when performing conventional, two-dimensional gating.  
Briefly, the computational steps underlying t-SNE are: first, the calculation of a 
pairwise similarity matrix for all data-points, based on their high-dimensional 
distances. Next, a low-dimensionality similarity matrix is calculated based on initially 
random locations for each cell in the two (or three) t-SNE dimensions. In an iterative 
process, the algorithm then tries to minimize the difference between the high- and 
low-dimensional similarity matrices, thereby adjusting every cell´s position in the 
two-dimensional space. Recent improvements to t-SNE make use of the Barnes-Hut 
algorithm (van der Maaten 2014) which uses a tree-like structure to reduce the 
number of pairwise similarities that actually have to be calculated. This now allows 





Figure 9. viSNE map of healthy human bone marrow. (a) In a synthetic toy example, (1,000 points randomly 
distributed with normally distributed noise around a polynomial of the third degree) viSNE projects a one- 
dimensional curve embedded in three dimensions (left) onto two dimensions (right). The color gradient shows that 
points that are in close proximity in three dimensions remain in close proximity in two dimensions. (b) Application 
of viSNE to a healthy human bone marrow sample, stained with 13 markers and measured with mass cytometry, 
automatically separates cells into spatially distinct subsets based on the combination of markers that they express. 
Each point in the viSNE map represents an individual cell and its color represents its immune cell subset as 
designated by independent expert manual gating (manual gates are defined at the bottom). Gray points were not 
classified by manual gating. The axes are in arbitrary units. (c) Biaxial plots represent the same data shown in b, 
and show the gates drawn manually by expert operators. The colors of the squares match the colors in b. The 
actual manual gating used here is more complex and uses a series of biaxial plots to gate each population. Note, 
that unlike in b, no single biaxial plot spatially separates all subsets. (d) The same viSNE map shown in b is 
colored according to intensity of CD11b expression. Many of the cells within the dotted line gate were not 
classified as monocytes by manual gating (gray cells, b). Figure and legend taken from (Qiu et al. 2011). 
 
Similarly to SPADE, t-SNE incorporates random seeds and thus the results from 
multiple runs may visualize the data differently. This can be prevented by manually 
defining a random seed. On the resulting t-SNE map, different immune 
subpopulations will visually appear as distinct clusters, however t-SNE does not per 
se assign single cells to defined clusters. This can be accomplished either by 
subsequent manual gating on the t-SNE map or by using automated clustering 
algorithms. Prominent examples of such clustering methods are ACCENSE 
(automatic classification of cellular expression by nonlinear stochastic embedding) 
(Shekhar et al. 2014) or DensVM (Becher et al. 2014), both employing a density-peak 
detection approach on the two-dimensional t-SNE map.   
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1.6.5.3. Citrus – Identification of stratifying subpopulations 
Visualization of multi-parameter cytometry data is a helpful first step in making high-
dimensional data accessible to scientists for further investigation. In many cases, such 
subsequent questions involve the comparison of two sets of samples in search of 
cellular subpopulations with distinctive abundance or expression levels. The 
algorithm named Citrus provides an unsupervised and automated process that 
combines computational identification of cellular subpopulations with various 
association models to reveal stratifying clusters and cellular responses that are best 
predictive, or best correlated with the experimental endpoint (Bruggner et al. 2014). 
For example, such experimental endpoints can be affiliation to a certain group, good 
or poor clinical outcomes or even survival time. As an input, Citrus receives 
cytometry data of two or more sets of samples associated with distinct groups, e.g. 
patient and control groups or different stimulation regimes. Citrus then automatically 
defines cellular populations and calculates cluster characteristics. After applying a 
chosen association model, Citrus provides the user with a list of clusters behaving 
differentially in the two sample groups, as well as characteristics of these clusters 
represented in histograms and bar plots (Figure 10). Additionally, Citrus provides a 
model to predict the affiliation of samples to one of the input groups using regularized 
classification.  
Shortly, the Citrus algorithm combines all samples into one aggregate dataset before 
identifying cell populations by hierarchical clustering of phenotypically similar cells. 
Importantly, only clusters of populations that are more abundant than the user-defined 
minimum cluster-size threshold will be included in the subsequent analysis. Next, 
cells are assigned back to the individual samples and cluster characteristics, such as 
median expression level for all markers, are calculated. Subsequently, Citrus employs 
a regularized classification model to identify stratifying clusters which are used to 





Figure 10. Overview of Citrus. Cells from all samples (i) are combined and clustered by using hierarchical 
clustering (ii). Descriptive features of identified cell subsets are calculated on a per-sample basis (iii) and used in 
con- junction with additional experimental metadata (iv) to train a regularized regression model predictive of the 
experimental endpoint (v). Predictive subset features are plotted as a function of experimental endpoint (vi), along 
with scatter or density plots of the corresponding informative subset (vii). In this example, the abundance of cells 
in subset A was found to differ between healthy and diseased samples (vi; H, subset A abundance in healthy 
patients; D, subset A abundance in diseased patients). Scatter plots show that cells in subset A have high 
expression of marker 1 and low expression of marker 2 relative to all measured cells (shown in gray). Figure and 
legend taken from (Bruggner et al. 2014). 
 
1.6.5.4. PhenoGraph – clustering in high-dimensional space 
While both t-SNE and SPADE facilitate the visualization of phenotypically similar 
cell subsets in high-dimensional datasets, these analysis approaches do not directly 
assign cells to distinct clusters. Also, the density-peak detection algorithms mentioned 
above (ACCENSE and DensVM) (Shekhar et al. 2014; Becher et al. 2014) do not 
take the entire dimensionality of a given dataset into account. To do so, a novel 
algorithm was recently developed and termed PhenoGraph (Levine et al. 2015). 
PhenoGraph models the high-dimensional space using a k-NNG, in which each cell is 
depicted as a node that is connected to its neighbors by edges. In this graph, 
phenotypically similar clusters of cells will be represented as sets of highly 
interconnected nodes. These can be seen as neighborhoods or communities of cells, 
and can be partitioned in high-dimensional space using similar community-detection 
algorithms which are being used for the analysis of social networks. The resulting 
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clusters can then be visualized on a t-SNE map, which often corresponds well with 
the PhenoGraph clustering, or alternatively on a heat map, which will show the 
expression levels of selected marker across all found clusters (Figure 11). 
 
 
Figure 11. Overview of phenograph clustering. (a) PhenoGraph method for clustering high-dimensional single-
cell data. Each node in the neighbor graph represents one of 500 random cells from a healthy donor (H1) colored 
by CD34 expression. CD34+ HSPCs form a dense subgraph and are automatically assigned to a single 
subpopulation. (b) HSPCs identified by PhenoGraph from donor H1. This subpopulation (red histograms) had a 
CD34+/CD45low phenotype relative to the other cells in the sample (gray histograms). Each PhenoGraph 
subpopulation contained cells from all perturbations, permitting analysis of 224 signaling responses. Figure and 
legend adapted from (Levine et al. 2015). 
 
The reported application of PhenoGraph to high-dimensional data of human bone 
marrow derived from healthy donors as well as acute myeloid leukemia (AML) 
patients (Levine et al. 2015) suggests that this method is superior to previously 
available clustering methods, and can resolve sub-populations as rare as 1 in 2000 
cells. In fact, one advantage distinguishing PhenoGraph from previous dimensionality 
reduction approaches is the addition of a second iteration process using the so-called 
Jaccard similarity coefficient. This computational step aids the identification of small 
cellular subsets (e.g. hematopoietic stem cells) that could potentially be obscured 
either by noise or by other larger cell populations.   
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1.6.5.5. FlowSOM – Self organizing high-dimensional data 
Another method for clustering and visualization of cytometry data is FlowSOM (Van 
Gassen et al. 2015). It is based on the principle of self-organizing maps (SOMs) 
which is an unsupervised technique for clustering and dimensionality reduction 
(Kohonen 1990). The workflow is outlined in Figure 12. After optional preprocessing 
steps, a SOM is built from the input data. SOMs are a type of artificial neural 
network, consisting of a grid of nodes, in which each node represents a point in the 
multidimensional input space. New points are added and classified with the node that 
is the closest neighbor. The grid is trained in such a way that nearby nodes resemble 
each other more than nodes that are further away. As the next step, the SOM is 
visualized as a minimal spanning tree (also used in SPADE, see 1.6.5.1). Lastly, a 
metaclustering step is performed, employing consensus hierarchical clustering. 
 
 
Figure 12. Overview of the four steps of the FlowSOM algorithm. (i) The fcs-files are read, compensated, 
transformed, concatenated and scaled, resulting in a matrix with a row for every cell, describing the measured 
marker values. (ii) A self-organizing map is trained on the matrix. The result is a grid of nodes, corresponding to 
cell clusters. Visualizations can be made showing the mean marker values of each node in star charts (a) or the 
concordance with a manual gating in pie charts (b). (iii) A minimal spanning tree is built, on which the same 
information can be visualized (c,d). We can also show mean marker values for specifically chosen markers, 
resulting in figures very similar to SPADE trees (e). (iv) A meta-clustering of the nodes is calculated, 
corresponding to an automatic gating procedure. This is indicated by the background color of the nodes, and can 





1.6.6. Practical considerations for automated data analysis 
1.6.6.1. Quality control 
The first practical aspect when starting to analyze high-dimensional data sets in an 
automated manner is to perform appropriate quality control (QC) and data pre-
processing. While proper QC of both the instrument and acquired data should always 
be part of any standard cytometry analysis workflow, it becomes even more relevant 
with increasingly complex experiments. In brief, QC should at least include validation 
of both the instrument and reagents used (e.g. non-specific binding of antibody, 
spillover due to metal impurity), and for fluorescence-based flow cytometry, the 
assessment of signal stability over time and especially potential artifacts arising from 
improper compensation (reviewed in (Perfetto et al. 2006)).  
 
1.6.6.2. Data transformation 
In addition, automated analysis of high-dimensional data asks for dedicated pre-
processing steps, especially data transformation. Epitope abundances measured by 
cytometry often follow normal distributions on a logarithmic scale (so called log-
normal distribution) with the variance of different cell populations depending on their 
intensity. Therefore, obtaining a suitable representation of the data across its entire 
intensity range is crucial for visualization and particularly for automated analysis. To 
do so, different transformation methods can be employed (compared and reviewed in 
(Trotter 2007) and (Finak et al. 2010)). In the context of the aforementioned 
algorithms, the data are frequently transformed using a logicle or arcsinh 
transformation (Parks et al. 2006; Herzenberg et al. 2006). This transformation was 
introduced for flow cytometry data to allow negative values, which originate, on the 
one hand, from baseline subtractions and, on the other hand, from spectral overlap 
correction (compensation), while maintaining logarithmic like scaling for large 
parameter values.  
 
1.6.6.3. Data normalization 
Another important pre-processing step when performing automated analysis is data 
normalization. This standardization can be employed on multiple levels. In general, 
we here refer to normalization as the process of using internal or external control 
 
 29 
values to express the acquired data on a common scale, thus improving comparability 
between multiple measurements. A first level of normalization is often to adjust 
measurements to differences that might occur in instrument sensitivity (over time or 
across different machines), and thus might influence measured values. In both, flow 
and mass cytometry, the addition of standardized beads with known signal intensity 
can be used for this purpose (Perfetto et al. 2006; Finck et al. 2013).  
Further, in settings in which multiple samples with technical inter-sample variation 
(e.g. due to different cytometers, sample handling, staining process, etc.) should be 
included in the same automated analysis, per-channel basis normalization can help 
automated algorithms to identify respective cellular populations across many samples. 
Different approaches have been developed for this purpose, such as alignment of 
prominent landmark features or features of defined subpopulations (Hahne et al. 
2010; Finak et al. 2014). In addition, to help match populations from multiple 
samples, normalization can also be applied in order to reduce differences in the 
contribution of markers and antibodies with different dynamic ranges. Large 
separations between positive and negative populations do not necessarily reflect the 
biological differences between those populations, therefore adjusting the range to a 
common scale might be desired. This can be done by normalizing the data on a per-
channel basis e.g. to the z-score (also called standard score), thus expressing 
measured intensities as numbers of standard deviations above or below the mean. 
Alternatively, data points can also be scaled to any chosen channel-specific percentile 





2. Aims of the study 
2.1. Part I – Establishing the role of GM-CSF in MS 
The first aim of this study was to reveal whether the preclinical finding that GM-CSF 
production by TH cells plays a crucial role in the pathogenesis of autoimmune 
neuroinflammation would be applicable into MS in humans. Secondly, given that TH 
cell-derived GM-CSF indeed shows involvement in MS, our next objective was to 
determine the factors regulating the production of GM-CSF in human TH cells in 
order to better understand and possibly in the future interfere with the emergence of 
such pathogenic TH cells. In addition, the genetic basis of MS was recently well 
established, however how this translates into pathogenic mechanisms resulting in the 
onset of neuroinflammatory disease remains elusive. It would thus be of great interest 
to examine genetic risk factors and their potential influence on GM-CSF production 
which would constitute one possible pathogenic mechanism in MS and thus aid our 
fundamental understanding of the disease. 
 
2.2. Part II – High-dimensional analysis of TH cell polarization in MS  
Especially TH cell differentiation and cytokine production were found to be critical 
mechanisms in the pathogenesis of MS, however the exact identity of the TH cell 
polarization pattern and responsible cytokines underlying MS pathology are still 
under debate. Therefore, we wanted to extend our previous studies on the role of GM-
CSF in MS by employing a high-dimensional and unbiased approach to reveal the 
breadth of cytokine production profiles of the entire TH cell landscape in MS using 
mass cytometry. Specifically, in a first step we planned to establish a comprehensive 
panel of heavy-metal isotope-labelled antibodies against the most important 
cytokines, activation markers and chemokine receptors. Using this panel in 
combination with recently developed algorithms for unbiased analysis of high-
dimensional data, our final aim was to identify distinct cellular profiles discriminating 




3. Results – Part I 
3.1. Regulation of GM-CSF production in human TH cells 
3.1.1. IL-2 induces the production of GM-CSF 
To reveal the most potent inducer of GM-CSF production in human TH cells, we 
activated (aCD3/aCD28, irradiated feeder cells) naïve TH cells from healthy donors 
in the presence of IL-23, IL-1b and IL-6, which have been demonstrated to drive GM-
CSF secretion in murine TH cells (Codarri et al. 2011; El-Behi et al. 2011), or with IL-
2. IL-23, IL-1b and IL-6 did not increase GM-CSF production by human TH cells 
(Figure 13a,b). Importantly, we noticed that IL-2 was able to substantially increase 
the expression of GM-CSF by human TH cells. Moreover, GM-CSF production 
observed without addition of exogenous cytokines was dependent on endogenously 
produced IL-2 (Figure 13c). Addition of TGF-β1 or TGF-b3 to induce IL-17A 
production negatively regulated GM-CSF secretion (Figure 13a,b and d-f), similar to 
what has been observed in murine T cells (El-Behi et al. 2011). The frequency of IL-
2Ra
+







Figure 13. IL-2 drives GM-CSF secretion by human TH cells. IL-2 drives GM-CSF secretion by human TH 







activated (aCD3/aCD28) in the presence of 10 ng ml
-1













 was determined by flow cytometry on day 7 (n=6). (c) Naïve TH 
cells were activated (aCD3/aCD28) in the presence or absence of neutralizing IL-2 antibody (n=7). Data are 
combined from three independent experiments. (d-h) Naive TH cells were activated as indicated in the presence or 
absence of the indicated TGF-b for 5 days (n=5). Shown are cumulative results of GM-CSF
+
 TH cells after aCD3 
activation (d) or after aCD3/ aCD28 activation (e), representative flow cytometric results (f) and cumulative 
results of IL-2Ra
 
expression on TH cells after aCD3 activation (g) and after aCD3/ aCD28 activation (h). For all 




3.1.2. IL-2Ra engagement drives GM-CSF in human TH cells 
CD28 costimulation is a strong inducer of IL-2 production in T cells. To precisely 
control IL-2 levels, we activated naïve TH cells with only aCD3 in the presence of 
irradiated feeder cells and the respective cytokines. Addition of IL-6 and IL-1b led to 
a moderate increase in the frequency of GM-CSF producing TH cells, but only 
marginally affected the concentration of secreted GM-CSF (Figure 14a,b).  
 
 









) were activated (aCD3) in the presence of 10 ng ml
-1
 of the indicated cytokine for 5 days (n=6). 
Shown are cumulative results of GM-CSF
+
 in TH cells (a) and the level of secreted GM-CSF in the cell culture 
supernatant (b). n.d. not detected. (c-e) Naïve TH cells as in (a,b) were activated (aCD3) in the presence of the 
indicated concentration of IL-2 for 5 days. Shown are the frequency of GM-CSF
+
 and IFN-g+ TH cells (c, n=6), 
GM-CSF levels in the cell culture supernatant (d, n=12) and the frequency of IL-2Ra
+
 TH cells (e, n=4). (f) GM-
CSF levels in serum of healthy individuals was analyzed by ELISA (n=99). (g,h) Representative example (g) and 
cumulative results (h) of sorted naïve TH cells which were activated (aCD3) in the presence of 10 ng ml
-1
 IL-2 and 
analyzed for GM-CSF secretion and IL-2Rα expression on day 5 (n=12). (i) Blocking of the IL-2Rα by 
monoclonal antibodies during the activation of naïve TH cells in the presence of 10 ng ml
-1
 IL-2 for 5 days (n=6). 
Data are combined from three independent experiments. For all figures throughout, error bars show mean±s.e.m. 
 
In contrast, IL-2 induced a strong increase in the frequency, as well as in the level of 
secreted GM-CSF. IL-2 promoted GM-CSF in a dose-dependent manner, in terms of 
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the frequency of cytokine producing TH cells, as well as in the level of secreted 
cytokine (Figure 14c,d). Production of other cytokines such as IFN-g was only mildly 
increased. Similar to the frequency of GM-CSF secreting cells, IL-2Ra
+
 TH cells 
increased depending on the IL-2 concentration (Figure 14e). Of note, the employed 
concentrations of recombinant IL-2 were within the range of IL-2 levels measured in 
the serum of healthy individuals (Figure 14f). After activation in the presence of IL-2, 
all GM-CSF producing TH cells expressed the IL-2Rα (Figure 14g,h). This expression 
was critical for the induction of GM-CSF through IL-2, as shown by blocking of IL-
2Rα with monoclonal antibodies, which drastically reduced GM-CSF secretion by TH 
cells (Figure 14i). Together, this highlights the importance of the IL-2Ra for the 
induction of GM-CSF production by human TH cells. 
 
3.1.3. IL-2 drives GM-CSF production independent of proliferation 
IL-2 is known to drive TH cell expansion. We therefore tested whether this might 
contribute to the observed increase in the frequency of GM-CSF secreting TH cells. 
We activated naïve TH cells in the presence of IL-2, IL-7 or IL-15, cytokines known 
to promote TH cell expansion (Figure 15a). IL-2 and IL-15 both induced strong GM-
CSF production in TH cells (Figure 15a,b). IL-7 strongly stimulated proliferation 
while it only slightly affected the frequency of GM-CSF secreting TH cells, indicating 
that expansion per se is not sufficient to induce GM-CSF production (Figure 15a,b). 
Consequently, the frequency of GM-CSF secreting TH cells did not correlate with the 
calculated percentage of divided cells (Figure 15c). To further support this, we 
determined the cell cycle state of GM-CSF secreting cells after activation of TH cells 
in the presence of those cytokines. IL-2, IL-7 and IL-15 all induced proliferation 
(Figure 15d), however we found that the majority of GM-CSF secreting cells were not 
actively proliferating, thus demonstrating that proliferation is not essential for GM-





Figure 15. GM-CSF secretion is independent of proliferation. (a) Representative examples and (b) cumulative 
results of sorted naïve TH cells which were activated (aCD3) in the presence of 10 ng ml
-1
 of IL-2, IL-7 or IL-15 
and analyzed for GM-CSF expression and proliferation on day 5 (n=10). (c) Normalization of the frequency of 
GM-CSF secreting TH cells by the calculated frequency of divided TH cells (n=10). (d,e) Cumulative results (d) 
and representative example (e) of purified TH cells which were activated (aCD3) in the presence of the indicated 
cytokines and analyzed for cell cycle state and GM-CSF production on day 2 (n=8). (f) Frequency of proliferating 
(Ki-67
+
) TH cells within the fraction of GM-CSF
+
 TH cells after activation in the presence of 10 ng ml
-1
 of the 
indicated cytokine for 4 days (n=7,6,6,3 respectively). Data are from one representative of two independent 
experiments. Each symbol represents a single individual. For all figures throughout, error bars show mean±s.e.m. 
 
3.1.4. GM-CSF expression is regulated via STAT5 
IL-2 and IL-15 both induce strong phosphorylation of STAT5. We investigated 
whether this signaling pathway is initiating GM-CSF induction in human TH cells. 
Therefore, we stimulated TH cells with different gc-cytokines or different IL-2 
concentrations to induce varying levels of pSTAT5. The frequency of GM-CSF+ TH 
cells closely correlated with STAT5 phosphorylation, indicating that pSTAT5 directly 
drives GM-CSF expression (Figure 16a,b). Using in silico analysis, we found the 
human GM-CSF (CSF2) promoter to contain a STAT5 binding site 
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(chr5:131,409,289-131,409,300). Further supporting this concept, we observed loss of 
IL-2-induced GM-CSF production on protein and mRNA level upon specific STAT5 
inhibition (Nelson et al. 2011) in TH cells (Figure 16c-e). GM-CSF production 
induced by endogenous IL-2 was similarly reduced by STAT5 inhibition.  
 
 








) were activated (aCD3) in the presence of the indicated cytokine for 5 days. GM-CSF secretion 
and STAT5 phosphorylation (10 min of restimulation with the indicated cytokine in the same concentration) were 




 TH cells after 
stimulation in the presence of different gc-cytokines (a, n=4) and after stimulation with different IL-2 
concentrations (b, n=5). (c,d) Naïve TH cells as in (a,b) were activated with aCD3 + IL-2 (c, n=16) or 
aCD3/aCD28 (d, n=8) with or without inhibition of STAT5 phosphorylation (2.5 µg ml
-1
 pimozide). (e) Purified 
TH cells were activated (aCD3) in the presence of IL-2 with or without the STAT5 inhibitor for 16 h before CSF2 
mRNA levels were analyzed by quantitative real-time PCR (n=8). Data are combined from two independent 
experiments. Each symbol represents a single individual. For all figures throughout, error bars show mean±s.e.m. 
 
3.2. The influence of regulatory T cells 
3.2.1. Treg cells inhibit GM-CSF
+
 TH cells through IL-2 deprivation 
Treg cells are capable of regulating cytokine secretion by auto-aggressive T cells 
through various mechanisms (Vignali et al. 2008) and alterations in this suppression 
have been reported in MS patients (Viglietta et al. 2004; Carbone et al. 2014). We 
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found Treg cells to suppress IL-2 induced GM-CSF production by conventional TH 
cells (Figure 17a,b). This suppression functions mostly independently of TGF-b or 
IL-10, but rather through deprivation of IL-2 (Figure 17c). Regulation of IL-2 levels 
by Treg cells thus has a major impact on the effector function of TH cells through 
direct modulation of GM-CSF production. 
 
 
Figure 17. Regulatory T cells suppress GM-CSF production by deprivation of IL-2. (a,b) Sorted naïve (TN) 
and regulatory T cells (Treg) were co-cultured in a 1:1 ratio and activated (aCD3/aCD28) in the presence of 10 
ng/ml IL-2 and the indicated blocking antibodies for 5 d (n=9,9,4,3 respectively). Shown are representative 
examples of GM-CSF secretion and CFSE dilution (a) and cumulative results of GM-CSF secretion (b). Data are 
combined from three independent experiments. (c) Fluorescent imaging of TN (CFSE labelled) and Treg cells 
(CellTrace Violet labelled) which were stimulated together with 10 ng/ml IL-2Fc for 10 min. Each symbol 
represents a single individual. For all figures throughout, error bars show mean±s.e.m. 
 
3.3. GM-CSF expression in multiple sclerosis 
3.3.1. GM-CSF secreting TH cells are elevated in MS patients 
GM-CSF is currently considered to be a promising therapeutic target in several 
autoimmune diseases such as rheumatoid arthritis (RA) (Burmester et al. 2013) and 
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MS (NCT01517282). Therefore, we quantified the ex vivo frequency of GM-CSF, IL-
17A and IFN-γ secreting memory TH cells in the peripheral blood of MS patients 
compared to OND patients (Table 1 - Table 3). We observed that untreated MS 
patients had a significantly higher frequency of GM-CSF producing memory TH cells 
compared to OND patients (17.0% vs. 11.5%, Figure 18a,b).  
 
 
Figure 18. MS patients have elevated frequencies of GM-CSF secreting TH memory cells. (a) Representative 
GM-CSF and IFN-γ production and (b) cumulative data from PBMCs of untreated RRMS patients and OND 







 memory TH cells by flow cytometry (OND n=22; MS n=27). (c) Effect of immune-modulatory 




 (untreated n=27, treated n=17) and IL-17A
+
 
(untreated n=27, treated n=16) memory TH cells. Data are combined from more than three independent 
experiments. (d) CFS serum levels of MMP9 and NFL in RRMS patients with a low (n=14) or high (n=14) 
frequency of GM-CSF
+
 memory TH cells. (e) Ex vivo frequency of GM-CSF
+
 memory TH cells in MS patients 
(RRMS/CIS) with 0-5 (n=12) vs. MS patients with >5 (n=39) T2 MRI lesions. Data are combined from more than 
three independent experiments. Each circle represents a single individual. (b,c,e) lines represent the median (d) 
error bars show mean±s.e.m.  
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A similar 1.5-fold increase (15.5% vs. 10.1%) was observed in an independent 
validation cohort of MS and OND patients, yet marginally above the statistical 
threshold (p=0.052, Figure 19a). Additionally, we could replicate the previously 
reported (Becher et al. 1999) increase in IFN-γ producing memory TH cells in MS vs. 
OND (21.7% vs. 16.0%). In agreement with previous reports (Jamshidian et al. 2013), 
we observed only a modest increase (1.0% vs. 0.8%) in the frequency of IL-17A 
secreting TH cells. Interestingly, patients treated with immune-modulatory drugs had a 
significantly reduced frequency of GM-CSF secreting TH cells compared to untreated 
patients (10.8% vs. 17.0%, Figure 18a,c and Figure 19b). A similar effect of immuno-
modulatory treatment, albeit less pronounced, was observed in the frequency of IFN-γ 
producing memory TH cells (17.3% vs. 21.7%). We did not observe any significant 
difference in the percentage of IL-17A producing memory TH cells upon therapy. The 
proportion of IL-2Ra
+
 memory TH cells did not significantly differ between the 
patient groups (Figure 19c). Taken together, GM-CSF
+
 TH cell frequencies are 
elevated in MS and decrease upon immune-modulatory therapy. 
 
 
Figure 19. MS patients from an independent validation cohort have increased frequencies of GM-CSF 
producing TH cells. (a-c) Frequency of cytokine secreting and IL-2Ra
+
 memory TH cells determined by flow 
cytometry without prior in vitro culture (MS n=14, OND n=14, treated MS n=8). Shown are cytokine production 
in OND vs. MS patients (a) as well as in untreated vs. treated MS patients (b) and the frequency of IL-2Ra
+
 
memory TH cells in OND vs. MS patients (c). Data are combined from three independent experiments. Each 






 TH cells coincide with biomarkers for disease severity 
Furthermore, we analyzed whether increased GM-CSF production by TH cells is 
associated with cerebrospinal fluid (CSF) biomarkers of disease progression and 
severity such as matrix metalloproteinase 9 (MMP9), an indicator of brain-blood 
barrier integrity (Ram et al. 2006), as well as neurofilament-light chain (NFL), a 
marker for neuronal damage (Lycke et al. 1998). MS patients with an elevated 
frequency (above a median of 15.3%) of GM-CSF secreting TH cells had strongly 
elevated CSF levels of MMP9 (2.9 vs. 92.4 ng ml
-1
, Figure 18d) as well as NFL (810 
vs. 1677 ng L
-1
), compared to MS patients with a low (below median) frequency of 
GM-CSF producing TH cells. Additionally, we observed an increase in GM-CSF 
producing TH cells in MS patients with more T2 MRI lesions (Figure 18e). Taken 
together, these observations indicate that patients with higher proportions of GM-CSF 
producing TH cells may have a more severe MS phenotype. 
 
3.4. Genetic modulation of GM-CSF production 
3.4.1. IL2RA risk alleles convey an elevated frequency of GM-CSF
+
 TH cells 
Given the relationship between MS and the frequency of GM-CSF
+
 TH cells, together 
with the role of IL-2 in the regulation of GM-CSF, we tested whether MS-associated 
IL2RA polymorphisms modulate GM-CSF production and thereby increase the risk of 
MS in healthy individuals (Table 4). In agreement with previous reports (Dendrou et 
al. 2009), we observed increased surface expression of IL-2Rα on naïve TH cells in 
individuals with rs2104286 risk (A/A) vs. protective alleles (A/G or G/G, Figure 20a). 
We analyzed whether this risk allele-mediated increase in IL-2 responsiveness of 
naïve TH cells translates into corresponding frequencies of GM-CSF-producing 
memory TH cells. In vitro stimulation (aCD3 and 10 ng ml
-1
) of sorted naïve TH cells 
with rs2104286 risk alleles resulted in higher frequencies of GM-CSF producing 
memory TH cells when compared to TH cells carrying protective alleles (Figure 20b). 
Additionally, sorted IL-2Ra
+
 naïve TH cells produced higher levels of GM-CSF after 
activation in the presence of IL-2 compared their IL-2Ra
-
 counterpart (Figure 20c). 
We next analyzed whether this modulation of GM-CSF production also occurs in vivo 
and observed that individuals with rs2104286 risk alleles had a substantially increased 
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number of GM-CSF producing memory TH cells compared to individuals with 
protective alleles (Figure 20d). The frequency of IFN-γ and IL-17A secreting memory 
TH cells was not affected by rs2104286. 
 
 
Figure 20. MS-associated IL2RA risk alleles augment GM-CSF producing TH cells. (a) Ex vivo surface 
expression of IL-2Rα on naïve TH cells from healthy individuals with a protective (G/G or A/G) or risk IL2RA 
genotype (A/A) at rs2104286, determined by flow cytometry (protective n=14, rs2104286 n=25). Data are 
combined from more than three independent experiments. (b) Sorted naïve TH cells were activated in vitro (aCD3) 
in the presence of 10 ng ml
-1
 IL-2 and then analyzed for GM-CSF expression by flow cytometry on day 5 
(protective n=10, rs2104286 n=16). Data are combined from more than three independent experiments. (c) Naïve 
TH cells were sorted according to IL-2Ra
 
expression and then activated (aCD3) for 5 days in the presence of 10 
ng ml
-1
 IL-2 (n=10). Data are combined from two independent experiments. (d) PBMCs from healthy individuals 







memory TH cells (protective n=31, rs2104286 n=46). (e) Individuals with rs2104286 protective alleles were further 
analyzed for ex vivo GM-CSF expression with regard to rs12722489 (protective n=28, rs12722489 n=14). (f) Ex 
vivo frequency of GM-CSF
+





 n=15). Data are combined from more than three independent experiments. (g,h) Purified TH cells 
were cultured in the presence of 0-10 ng ml
-1





 TH cells at 10 ng ml
-1
 IL-2 (protective n=28, rs2104286 n=40, g) and the frequency of GM-CSF
+
 TH 
cells at IL-2 concentrations from 0-10 ng ml
-1
 (protective n=30, rs2104286 n=34, h). (i) Gene-dosage effect of 
rs2104286 on the frequency of GM-CSF
+
 TH cells, cultured as in (g,h), assuming a linear gene-phenotype relation 
(G/G n=5, A/G n=33, A/A n=45). Data are combined from more than three independent experiments. Each symbol 
represents a single individual. (a-g) lines represent the median, (h,i) error bars show mean±s.e.m. 
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Several SNPs have been identified within the IL2RA locus, including rs12722489, 
which is in modest linkage disequilibrium with rs2104286. Recent data show that of 
these two, only rs2104286 increases the risk to develop MS (Beecham et al. 2013). 
Accordingly, rs12722489 did not alter the frequency of GM-CSF producing TH cells, 
demonstrating that the observed increase in GM-CSF production by rs2104286 is a 
specific consequence of risk-driving genetic variants and not other IL2RA SNPs 
(Figure 20e). Furthermore, we found the strongest genetic association with MS, HLA-
DRB1*15:01, to have no influence on the frequency of GM-CSF expressing TH cells 
(Figure 20f), indicating that modulation of GM-CSF expression is not a general 
mechanism of MS-associated risk genes. Additionally, HLA-DRB1*15:01 has been 
reported to enhance autologous T cell proliferation (Mohme et al. 2013), further 
indicating that elevated proliferation is largely disconnected from the observed 
increase in GM-CSF production.  
 
3.4.2. IL2RA-influence on GM-CSF is preserved upon IL-2R engagement 
To directly assess the impact of the IL2RA SNP rs2104286 on IL-2R signaling, we 
additionally measured GM-CSF secretion after stimulating TH cells with IL-2 in the 
absence of TCR-engagement. Individuals with MS-associated risk alleles again 
showed a significantly higher number of GM-CSF secreting TH cells compared to 
donors carrying protective alleles (Figure 20g). As observed also immediately ex vivo, 
the frequency of IFN-γ secreting TH cells did not differ significantly between groups 
upon IL-2 stimulation. The increased frequency of GM-CSF producing TH cells in 
individuals with rs2104286 risk alleles was maintained at different IL-2 
concentrations (Figure 20h). Lastly, we observed a gene-dosage effect of the MS-
associated rs2104286 risk allele on the frequency of IL-2 stimulated GM-CSF 




3.5. GM-CSF expression by cytotoxic T cells 
We found that GM-CSF production by CD8
+
 T cells is not modulated by MS-
associated risk genes or by MS disease (Figure 21a-c). This specificity therefore 
underlines the importance of GM-CSF production by human TH cells in the context of 
MS pathology.  
 
Figure 21. GM-CSF production by CD8
+
 T cells is not altered in the context of MS. (a-c) The frequency of 
cytokine secreting CD8
+
 T cells determined by flow cytometry without prior in vitro culture. Shown are a 
representative GM-CSF and IFN-g secretion profile of CD8
+
 T cells (a), cumulative frequencies of GM-CSF 
secreting CD8
+





 T cells with a protective (G/G or A/G) or risk IL2RA genotype (A/A) at rs2104286 (protective 
n=37, rs2104286 n=52; c). Data are combined from more than three independent experiments. Each circle 





4. Results – Part II 
4.1. Establishing a mass cytometry workflow 
4.1.1. Design of the metal-metal isotope labeled antibody panel 
In order to extend our previous studies on the role of GM-CSF and other cytokines in 
MS, we employed high-dimensional mass cytometry to further explore the breadth of 
cytokine production profiles, focusing on TH cells but also investigating other 
immune cell lineages. We designed a panel of heavy-metal isotope-labeled antibodies 
against 36 antigens with a total of 46 measured parameters measured per cell (Figure 
22). Comprising a broad range of lineage markers, this panel was designed to identify 
all major immune populations (CD4
+
 T cells, CD8
+
 T cells, gdT cells, B cells, NK 
cells and monocytes) found in human PBMCs. 
 
 
Figure 22. Antibody panel for mass cytometric exploration of TH cell polarization. Antigens were chosen 
based on their importance in defining cellular subsets and lineages or based on prior reports indicating a possible 
involvement in MS. Monoclonal anti-human antibodies against the listed antigens were then obtained either pre-
conjugated to heavy-metal isotopes or as purified antibodies which were then conjugated in house. Clones, 
suppliers and metal isotopes for all antibodies are listed in Table 6. The indicated categories were used in the 




In order to perform an in-depth analysis of the TH cell subsets, we included a wide 
range of cytokines currently implicated in the pathogenesis of MS (Navikas and Link 
1996; Becher and Segal 2011; Amedei et al. 2012) as well as other cytokines that 
have been suggested to define or contribute to a separate TH cell lineage (Sallusto and 
Lanzavecchia 2009; O’Shea and Paul 2010). Additionally, we included multiple 
chemokine receptors which were shown to be differentially expressed on various TH 
cell subsets (Appay et al. 2008; Mahnke et al. 2013), as well as maturation and 
activation markers, providing further insight into the state of immune activation. All 
antibodies were purchased either in purified form and then conjugated (see section 
6.11.1) or obtained pre-conjugated to heavy-metal isotopes. Next, we established a 
staining protocol, optimized for the simultaneous detection of intracellular cytokines, 
as well as delicate surface markers such as chemokine receptors (see section 6.11). In 
short, we first stimulated the cells with PMA/ionomycin for 4h in the presence of a 
golgi-inhibitor. Next, we performed staining against surface markers and chemokine 
receptors simultaneously at 37°C (Berhanu et al. 2003) before fixation with 1.6% 
PFA and intracellular staining at 4°C for 1h. Using this protocol, we were able to 
obtain an optimal combination of surface marker, chemokine receptor and cytokine 





Figure 23. Cytokine and surface marker staining of human PBMCs using mass cytometry. Human PBMCs 
form healthy donors were stained with the antibodies against (a) surface markers, (b) chemokine receptors and (c) 
cytokines as listed in Table 6 and acquired on a CyTOF2 mass cytometer. Data was exported as fcs-files and 
uploaded to the cytobank website (www.cytobank.org). Plots shown are gated in live, single cells.  
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4.1.2. Establishing live cell barcoding 
The availability of numerous channels also facilitates the use of mass-tag cell 
barcoding techniques without having to sacrifice the detection of other potentially 
important parameters. For this, cells are labeled with a specific combination of heavy-
metal isotope-conjugated antibodies (Figure 24a). Subsequently, multiple barcoded 
samples can be combined and stained simultaneously within the same reaction tube, 
thereby virtually eliminating inter-sample staining variability and deviations during 
the acquisition process. Additionally, barcoding drastically reduces the number of 
undetected duplets. After acquisition, individual samples can be debarcoded by 
automatically gating on the specific combination of isotopes (Zunder et al. 2015). We 
established a barcoding scheme using a total of seven differently conjugated a-CD45 
antibodies allowing for up to 35 unique combinations with a 7-choose-3 barcoding 
scheme (depicted for a 6-choose-2 scheme in Figure 24a,b). 
 
 
Figure 24. CD45-based live cell barcoding for mass cytometry. (a) Barcoding scheme for a 15-sample 
barcoding with a 6-choose-2 pattern. Alternatively, we employed a 7-choose-3 pattern with which we were able to 
barcode up to 35 samples. These patterns ensure that no duplets of cells from different samples are mistaken as 
another barcode. (b) Representative sample stainings of the seven a-CD45 antibodies used. Samples were then 
identified using an automated gating software (Zunder et al. 2015).  
 
4.2. High-dimensional analysis of immune populations in MS patients 
4.2.1. Algorithm-guided definition of immune lineages 
After having established a comprehensive panel, the according staining protocol and 
the barcoding method, we used these techniques to explore the breadth of cytokine 
production profiles and immune activation in different groups of MS and control 
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patients (see Table 5). In order to compare the results obtained from different cohorts, 
we performed the analysis on all samples together and only later assigned individual 














 T cells, B cells, NK cells, gdT cells and monocytes in order to investigate their 
modulation in MS. To do so, we employed the recently established FlowSOM 
algorithm (see section 1.6.5.5), which identifies cellular populations in a more 
unbiased and automated way by using the information provided from all measured 
channels instead of relying on strict two-dimensional gating (Figure 25a-d). 
 
 
Figure 25. Algorithm-guided analysis of immune populations in MS. (a) PBMCs from healthy controls (HC n 
= 28), other neurological diseases (OND n = 36), relapse-remitting MS (RRMS n = 40), secondary-progressive MS 
(SPMS n = 5) and primary-progressive MS (PPMS n = 4) donors were analyzed using the mass cytometry panel 
described in section 4.1. (b) The FlowSOM algorithm was used to assign all cells to an artificial neuronal network 
consisting of 100 initial nodes. The mean expression of all indicated markers is represented by the height of each 
part. (c) Nodes as in (b) were metaclustered (k = 8) and manually annotated based on the expression level of 
several lineage-associated markers. (d) The Barnes-Hut (BH) implementation of the t-SNE algorithm was used to 
visualize the dataset on a two-dimensional map. Annotated metaclusters from (c) are overlayed as a color-
dimension. (e) The frequency of all populations was compared in the control vs. different groups of MS patients. 








 are given as percent of their 




 percentile with a black horizontal line indicating the median. 
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FlowSOM first assigns all cells to nodes (Figure 25b) and subsequently merges 
similar nodes into metaclusters (Figure 25c). All markers were used as input for the 
algorithm, however since our aim was to define major immune populations, we 
increased the contribution of all lineage markers (see section 6.12.2). The number of 
metaclusters (k = 8) was suggested by the FlowSOM algorithm based on a variance-
measurement within the clusters. Based on the mean expression level of several 
lineage markers, the resulting eight metaclusters were then annotated as meaningful 
immunological populations. Additionally, the combined dataset was subjected to 
dimensionality reduction and visualization via t-SNE (Figure 25d), using the same 
increased contribution of lineage markers as above. Comparing the FlowSOM 
metaclustering results with the t-SNE projection showed a suitable correlation with 
the visually separate populations provided by t-SNE, thus further supporting the 
accuracy of the obtained populations. In a last step, the frequencies of all identified 
populations were compared between the groups of MS and control patients. Apart 
from an increased frequency of B cells in SPMS patients (26.4 ± 6.2% median ± 




 T cells, no 
overt modifications were observed on the population level. 
 
4.2.2. Defined cytokine-producing TH cell populations expand in MS 
Having automatically defined the major immune populations found in human 
PBMCs, we wanted to perform a more detailed analysis of their cytokine production, 
differentiation and activation markers and trafficking profiles in different groups of 
MS patients (Figure 26). First, we manually analyzed the production of GM-CSF, 
IFN-g and IL-17A by CD45RO
+
 TH cells, which all three have been implicated in MS 
pathogenesis. As with conventional flow cytometry (see section 3.3.1), we found that 
GM-CSF (8.8 ± 0.8% vs. 5.7 ± 0.8%, median ± s.e.m.) and to a lesser extend IFN-
g (15.6 ± 2.0% vs. 13.7 ± 1.7%, median ± s.e.m.), but not IL-17A production (1.6 ± 
0.2% vs. 1.6 ± 0.2% median ± s.e.m.) were increased in RRMS versus OND patients 
(Figure 26a,b). IL-17A production however seemed to be increased in PPMS vs. 
OND patients (3.9 ± 0.7% vs. 1.6 ± 0.2%, median ± s.e.m.). Additionally, in order to 
validate that mass cytometry can be a useful tool to study cytokine production by 
various immune cells, we analyzed whether the frequencies of cytokine positive cells 
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(obtained from the same patients) correlate when analyzed by mass versus flow 
cytometry (Figure 26c). Reassuringly, the two methods displayed a tight correlation, 
even with several years passing between the respective experiments.  
 
 
Figure 26. Fine mapping of altered memory TH cell polarization in MS. (a,b) Manual gating on GM-CSF, IFN-
g and IL-17A-producing TH in HC (n = 28), OND (n = 36), RRMS (n = 40), SPMS (n = 5) and PPMS (n = 4) 
confirms increased production of GM-CSF and IFN-g in MS using mass cytometry. (c) Correlation of the 
frequencies of GM-CSF, IL-17A and IFN-g-producing CD45RO
+
 TH cells from the same donors obtained with 
mass versus flow cytometry. The correlation co-efficient and the P-value were calculated using a linear regression 
model. (d) Co-expression of various cytokines, trafficking-associated antigens, and differentiation markers was 




 TH cells using the FlowSOM algorithm with increased weighing for 
cytokine markers and subsequent metaclustering (k = 15). The heatmap shows median expression levels of all 





 TH cells (black) and their respective frequencies in different groups of control and MS 
patients. (e) The t-SNE algorithm was used to project cells from all samples onto three different categorical axes, 
using the markers indicated in (c) as respective inputs. The expanded GM-CSF-producing clusters were overlayed 




 percentile with a black horizontal line indicating the median. All P-
values were calculated using a non-parametric Mann-Whitney-Wilcoxon test. Multiple comparisons corrections 
were performed with the Benjamini-Hochberg approach. *** = significant with false discovery rate (FDR) < 5%, 




IFN-g has been known for decades to be the signature cytokine of the TH1 lineage, 
however, recently also other subsets have been shown to produce IFN-g (see section 
1.3.1). GM-CSF has also been associated with multiple TH cell subsets. On the one 
hand, GM-CSF is driven by TH1 polarizing cytokines and on the other hand, it was 
initially described to be associated with the TH2 lineage. Therefore, we wanted to 
examine if the increased GM-CSF production in MS patients is due to the expansion 
of a specifically defined GM-CSF producing subset, co-expressing a particular set of 





 cells from all samples were clustered using the FlowSOM algorithm 
and increasing the weight of cytokines in this clustering (Figure 26d). Multiple known 
TH cell lineages could be identified, such as TH1-like populations (cluster 7, 8), TH2 
(cluster 1, 2, 3), TH17 (cluster 9), TH22 (cluster 10), TFH (cluster 6) and TREG (cluster 
15) populations. We did not detect a distinct cluster corresponding to TH9 cells. Also, 
CD103
+
 cells were present but not distinct enough in their overall marker expression 
profile to form a separate cluster.  
GM-CSF production was prominent in four different clusters, with co-expression of 
IFN-g (cluster 7) or co-expression of TH2 cytokines IL-3 and IL-4 (cluster 2) or IL-13 
(cluster 1). In RRMS patients, we found that specifically those GM-CSF producing 
subsets were expanded, which were associated with the TH1 lineage (cluster 7 ~1.9 
fold increase in RRMS vs. OND, cluster 7 ~1.8 fold). This was not the case with GM-
CSF
+
 clusters co-expressing TH2-like cytokines (clusters 1 and 2; Figure 26e). Lastly, 
we analyzed whether the specifically expanded clusters 5 and 7 display an exclusive 
trafficking or maturation/activation profile. As described previously (Cheng et al. 
2015), we employed the categorical t-SNE-based dimensionality reduction algorithm 
with three distinct sets of input dimensions, based on a broad categorization of the 
markers into cytokines, trafficking/homing and differentiation/activation (Figure 26f). 
We found that both clusters had a very defined cytokine production profile, as it was 
intended by weighing cytokine markers during the clustering, however their 




4.2.3. Cytotoxic T cells in MS 
Although TH cells are thought to be the main pathogenic mediators in MS, we wanted 
to make use of the high-dimensional power of mass cytometry which allows for the 
analysis of multiple cell types within the same experiment. Thus, we also investigated 
the polarization profiles of CD8
+
 cytotoxic T cells (TC) cells. As with CD4
+
 T cells, 




 T cells by manual gating 
(Figure 27a). Comparing MS and control patients, we found a tendency for increased 
production of IFN-g in RRMS vs. OND patients (57.6 ± 2.5% vs. 47.6 ± 5.1% median 
± s.e.m.), which was however not statistically significant (P = 0.16, Figure 27b).  
 
 
Figure 27. Modulation of CD45RO
+





 cells was determined by manual gating. (b) Cumulative result of manually gated cytokine positive 
cells in HC (n = 28), OND (n = 36), RRMS (n = 40), SPMS (n = 5) and PPMS (n = 4). (c) The FlowSOM 
algorithm was used to define TC subsets. As before, the contribution of cytokine markers was increased. (d) 
Frequency of clusters as defined in (c) in MS vs. control patients. (d) Categorical, one-dimensional t-SNE was 
used to further explore the trafficking profile of differentially modulated clusters 9 and 13. Vertical histograms 





percentile with a black horizontal line indicating the median. All P-values were calculated using a non-parametric 
Mann-Whitney-Wilcoxon test. Multiple comparisons corrections were performed with the Benjamini-Hochberg 
approach. *** = significant with FDR < 5%, ** = significant with FDR < 10%, * = significant with FDR < 15%.  
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Extending this preliminary analysis, we wanted to examine whether a particular TC 
subset, which is not only defined by the production of a single cytokine but by the 
whole set of (TC-relevant) antigens analyzed, would be specifically modulated in MS. 
Again we made use of the FlowSOM algorithm to automatically define TC sub-
populations with a focus on cytokine expression patterns (Figure 27c). We found 
clusters corresponding to multiple, previously described TC subsets also in terms of 
their expression of chemokine receptor expression profiles. Analyzing their potential 
role in different groups of MS patients, we found that two clusters were specifically 
modulated in their frequency in RRMS patients. A small population of TC cells co-
producing IL-13 and IL-4 (cluster 12) was specifically decreased in RRMS vs. OND 
patients (0.23 ± 0.13% vs. 0.08 ± 0.04% median ± s.e.m.) whereas a substantial 
cluster co-expressing TNF-a, IL-2 and IFN-g was increased (22.9 ± 1.3% vs. 17.2 ± 
2.8% median ± s.e.m.). Furthermore, exploring the trafficking profile of these clusters 
we found that while cluster 12 seemed to have a more homogeneous trafficking 









 cells (Figure 27d). 
 
4.2.4. B cells and NK cells in MS 




 T cells, the broad nature of our panel 
also allows the investigation of further immune cell populations in MS. Especially B 
cells were recently shown to be more important players in MS pathogenesis then 
previously appreciated (see section 1.3.4). We were able to analyze several 
maturation and activation markers, as well as cytokines expressed by B cells. The 
frequencies of GM-CSF, IL-6, IL-10 and TNF-a producing B cells were however not 
significantly modulated in our cohort of MS patients (Figure 28a). Likewise, there 
was no major modulation of the expression levels of investigated chemokine receptors 





Figure 28. Cytokine-production profiles of additional immune populations in MS. (a) B cells were manually 
analyzed for the frequency GM-CSF, IL-6, IL-10 and TNF-a positive cells in various groups of control and MS 
patients. HC (n = 28), OND (n = 36), RRMS (n = 40), SPMS (n = 5) and PPMS (n = 4). (b) Cytokine production 
by NK cells was analyzed analogously. (c) Categorical, one-dimensional t-SNE analysis was used to further 
characterize the GM-CSF producing NK cell subset. Vertical histograms represent the normalized median intensity 
of CD56 (black), CD25 (yellow) and GM-CSF (red) across the trafficking dimension. On the plot, GM-CSF 
expression is shown as a color dimension from grey (low) to red to yellow (high). (d) The frequency of CD56
bright
 
NK cells was determined by manual gating. All P-values were calculated using a non-parametric Mann-Whitney-
Wilcoxon test. Multiple comparisons corrections were performed with the Benjamini-Hochberg approach. *** = 
significant with FDR < 5%, ** = significant with FDR < 10%, * = significant with FDR < 15%.  
 
NK cells might also contribute to some degree to pathogenic and/or regulatory 
mechanisms in MS (see section 1.3.6). To investigate their possible modulation in 
different subsets of MS patients, we examined NK cell maturation and cytokine 
production based on the available markers. We did not detect a significant modulation 
of NK cell cytokine production in RRMS patients compared to OND patients (Figure 
28b). However, the few examined PPMS patients showed a decrease in a GM-CSF 
producing population in comparison to OND patients (5.3 ± 2.1% vs. 10.7 ± 2.2% 
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median ± s.e.m.). Further investigations using categorical t-SNE dimensionality 
reduction demonstrated that the GM-CSF
+
 NK cells can be divided into two distinct 
populations based on their differentiation marker profile (Figure 28c). Specifically, 
we found a GM-CSF producing population of CD56
bright





 NK cells (Clausen et al. 2003; Gasteiger et al. 
2013). Accompanying the decreased GM-CSF production in PPMS patients, the 
frequency of CD56
bright
 cells was also reduced in PPMS versus OND patients (3.9 ± 
0.9% vs. 7.4 ± 1.0%, median ± s.e.m., Figure 28d). Additionally, we found a down 
regulation of the median CD27 expression on NK cells in PPMS patients (~3-fold 
decrease of median intensity), further supporting modulated NK cell maturation and 
differentiation in this progressive form of MS and again demonstrating how a broad 
analysis using mass cytometry can reveal unexpected phenotypes on otherwise 





5.1. The role of GM-CSF in MS and other autoimmune diseases 
The molecular signature and functional properties of auto-aggressive T cells in 
chronic inflammatory disease remain a subject of intense research (Becher and Segal 
2011). GM-CSF has emerged as a major pro-inflammatory mediator in several 
preclinical models of autoimmune disease. For instance, T cells deficient of GM-CSF 
fail to transfer disease in an animal model of MS. Thus GM-CSF has, in contrast to 
other cytokines such as IL-17A or IFN-g, a non-redundant function in the 
development of autoimmune neuro-inflammation (Codarri et al. 2011). Of note, a 
recent phase II clinical trial showed therapeutic efficacy of GM-CSF neutralization in 
RA patients (Behrens et al. 2014) and a phase Ib trial in MS patients has just been 
completed, demonstrating the urgent need for a better understanding of the role of this 
cytokine in autoimmunity (Constantinescu et al. 2015).  
Supporting the involvement of GM-CSF in MS, we here report increased frequencies 
of GM-CSF producing TH cells in MS compared to control patients. In addition, we 
found increased levels of CSF biomarkers of MS disease progression and severity, as 
well as the number of MRI lesions, to correspond with GM-CSF expression in these 
patients. Interestingly, immuno-modulatory therapy in MS coincided with a reduction 
in the frequency of GM-CSF (but not IL-17A or IFN-g) secreting T cells. This is not 
likely due to a direct impact of therapeutic interventions on GM-CSF production, but 
rather that therapy-induced reduction in disease activity leads to a normalization of 
GM-CSF frequencies in TH cells. 
 
5.2. The regulation of GM-CSF by IL-2 signaling 
In contrast to mice, where numerous cytokines have been proposed to initiate GM-
CSF transcription (Codarri et al. 2011; El-Behi et al. 2011), we observed that in 
humans, IL-2 is a particularly strong driver of GM-CSF production. As we could 
show, activation of STAT5 seems to play a crucial role in this process, which has now 
also been confirmed by further studies in humans as well as in mice (Noster et al. 
2014; Sheng et al. 2014). Also in agreement with others, we found the GM-CSF-
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inducing capacity of IL-2 to be independent of the effect IL-2 has on proliferation 
(Noster et al. 2014). 
 
5.3. The genetic influence on GM-CSF production 
GWA studies firmly link polymorphisms in the IL2RA locus (rs2104286) with the risk 
to develop MS. However, the mechanism by which this polymorphism confers risk 
has been elusive. Here we found a significantly increased propensity of TH cells from 
individuals carrying IL2RA risk alleles to secrete GM-CSF. Rs2104286 is an intronic 
SNP, which has been shown to regulate mRNA expression of IL-2Ra (Dendrou et al. 
2009). We here confirm that individuals with rs2104286 risk alleles have increased 
levels of surface IL-2Ra on naïve TH cells. This elevated responsiveness of naïve TH 
cells from healthy individuals with risk alleles results in a higher propensity to 
develop GM-CSF-expressing effector TH cells. This finding mechanistically links a 
prominent genetic risk factor with the production of the pro-inflammatory cytokine 
GM-CSF by TH cells, extending previous studies exploring possible pathogenic 
mechanisms of IL2RA SNPs (Lowe et al. 2007; Maier et al. 2009b; Maier et al. 
2009a; Dendrou et al. 2009). We did not find any modulation of cytokine production 
by TH cells with regard to the strongest genetic risk factor of MS, the HLA-
DRB1*15:01, nor with regard to other polymorphisms in cytokine receptors such as 
the IL7R. Together, this further underlines the specificity of the observed modulation 
by the IL2RA and contributes to the emerging picture in which non-HLA variants 
influence the threshold of immune activation and the subsequent differentiation 
profile, whereas HLA variants rather define the tissue specificity of the immune 
attack (Dendrou et al. 2015). 
 
5.4. Mass cytometry for the in-depth analysis of clinical phenotypes 
This thesis also constitutes one of the first reports in which the relatively new 
technology of mass cytometry is used to perform a more comprehensive analysis of 
immune states, especially cytokine production, and their pertubations in 
autoimmunity (Nair et al. 2015). To ensure that mass cytometry in combination with 
automated algorithms for high-dimensional data analysis are a suitable tool, we 
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compared our results obtained from conventional flow cytometry with the outcome of 
our mass cytometric experiments we found a tight correlation between the two 
techniques (Nicholas et al. 2015). Mass cytometry has faced the drawback of reduced 
sensitivity in comparison to traditional flow cytometry (Bendall et al. 2012), however 
near-future hardware improvements will render these differences negligible. 
Nevertheless, also the existing configuration was sufficient to clearly identify 
cytokine positive cells and to determine the profile of chemokine receptor expression. 
Thus, the high-dimensional ability of mass cytometry is so far only rivaled by single-
cell RNA sequencing (Wu et al. 2014). 
 
5.5. Algorithm-guided data analysis 
Furthermore, we here employed automated algorithms in order to perform a more 
unbiased and automated analysis. This has been shown to be especially valuable when 
looking at high-dimensional associations of markers where strict two-dimensional 
gating might miss important phenotypes (Lugli et al. 2010; Pedreira et al. 2013; 
Chester and Maecker 2015). Several algorithms have been shown to perform equally 
well and in many cases even superior when compared to manual gating (Aghaeepour 
et al. 2013; Kvistborg et al. 2015). Also, as shown above, the automatically defined 
populations corresponded well to expected immune populations and they were 
coherent with visually distinct clusters on a t-SNE map. Additionally, analysis of 
cytokine co-expression would not have been possible without using clustering 
algorithms. Given the examined 13 cytokines, there are 2
13
 = 8’192 possible 
combinations, even without using any additional information provided by trafficking 
or activation profiles. While the biologically relevant number of actual populations 
might be considerably lower, this clearly underlines the advantage of unbiased and 
automated analysis approaches. Since we were especially interested in cytokine-
production this also provided the rationale to differentially weigh cytokine markers in 
the analysis. This approach resulted in clusters more homogeneous in terms of their 
cytokine expression profile while still making use of the information provided by 
other markers. Together, this enabled us to automatically define subpopulations of 
which the majority could be easily attributed with previously described biological 
functions and to study their possible modulation MS.   
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5.6. GM-CSF producing TH cells comprise several subsets 
Having established this tool set, we could firstly confirm the increase in GM-CSF 
producing TH cells in RRMS patients, which we also found by flow cytometry in 
combination with manual gating, thus validating our approach and its clinical 
relevance on an additional layer. Next, using algorithm-guided subdivision of TH 
cells, we found that GM-CSF producing TH cells are a heterogeneous population, 
comprising multiple subsets as defined by co-expression with other cytokines as well 
as specific profiles of trafficking and differentiation markers. More specifically, GM-
CSF production was observed by TH1, TH2 and also other TH cells. However, we 
found that TH1-associated clusters constituted the largest fraction of GM-CSF 
producing TH cells. We believe that this comprehensive analysis can help understand 
and consolidate contradictory reports in which GM-CSF production has been reported 
to be associated with and driven by TH17 (Codarri et al. 2011; El-Behi et al. 2011), 
TH2 and TH1-inducing cytokines (Kruger et al. 1996; Noster et al. 2014). A possible 
explanation is that in vitro skewing towards these lineages is likely to result in 
associated GM-CSF production. However, as we have shown above, IL-2 is by far the 
most potent of these factors and congruently, we found clinically important in vivo 
relevance of the IL-2 pathway through the influence of IL2RA genetic variants.  
We here demonstrated that both, IFN-g as well as GM-CSF production are increased 
in MS patients and that these two cytokines are substantially co-expressed in human 





are increased in MS supports the notion of an independent pathogenic role of GM-
CSF, also in the absence of IFN-g.  
 
5.7. Modulation of further immune populations in MS 
Making use of the high-dimensional power of mass cytometry and thus the ability to 
analyse multiple populations simultaneously, we also analsyed the differentiation and 
cytokine profile of CD8
+
 T cells, NK cells as well as B cells in MS. Consistent with 
our flow cytometry analysis, high-dimensional mass cytometry did not reveal 
modulation of GM-CSF production by CD8
+
 T cells in RRMS, although this has been 
reported by others (Rasouli et al. 2015). Instead we found a population of IFN-g and 
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TNF-a co-producing TC cells to be increased in RRMS patients, whereas a TC2-like 
population was decreased. This finding is consistent with the general modulation of 
these cytokines in MS, however the functional relevance of their production by CD8
+
 
T cells will remain debated. Nevertheless, this again underlines the ability of mass 
cytometry to perform comprehensive clinical studies in which multiple cell types can 
be investigated simultaneously. 
 
5.8. Conclusions 
This study resolves and integrates findings obtained in preclinical models with human 
disease by providing a direct link between a genetic risk trait in MS pathogenesis, IL-
2R signaling, and a feature of pathogenic T cells, namely GM-CSF production. 
Additionally, we demonstrate the usefulness of mass cytometry in combination with 
automated algorithms for the analysis of clinical phenotypes of various immune 
populations simultaneously. We here made use of this abilty for the precise 
characterization of the pathogenic profile of TH cells and its modulation in MS. 
Taken together, we hope that this report can contribute to our knowledge of TH 
biology in general, and that it might advance our important understanding of the role 
of these cells and their specific subsets in the pathogenesis of autoimmune disease. 
We are looking forward to see GM-CSF neutralization moving forward in clinical 
trials and hope that our findings might soon contribute to benefit patients with MS 





6.1. Healthy donor and patient samples for GM-CSF studies 
6.1.1. Human PBMC samples 
Healthy donors were recruited via the blood donation center Zurich, Switzerland with 
approval of the cantonal ethics committee Zurich. MS and OND patient samples 
(Table 1 - Table 3) were collected at the neurological clinics at Karolinska University 
Hospitals Solna and Huddinge. MS and OND samples for validation were collected at 
the Nottingham University Hospitals, UK. Informed consent was collected from all 
participants. DNA was isolated using the DNeasy blood and tissue kit (Qiagen). SNPs 
and the HLA-DRB1*15:01 (rs3135388, (de Bakker et al. 2006; Hafler et al. 2007)) 
genotype were determined using TaqMan SNP Genotyping Assays (Life 
technologies). Flow cytometric experiments and analysis was performed blinded with 
regard to disease and genotype. 
 
6.1.2. Characterization of patient cohorts 
Table 1. Clinical diagnosis/characterization of MS and OND patients in cohort 1 
 
 OND patients Detailed clinical characteristics n 
Psychosis 14 
Paresthesia 4 
 Narcolepsy 1 
 Benign tumor in brain 1 
 Lesions on peroneal nerve 1 
  Visual disturbance 1 
MS patients   
RRMS remission 40 
RRMS relapse 4 
 
Abbreviations: OND = other neurological disease (non-inflammatory), MS = multiple 
sclerosis, RRMS = relapse-remitting MS.  
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Table 2. Clinical diagnosis/characterization of MS patients in cohort 2 
 
 OND patients Detailed clinical characteristics n 
 Epileptic disorder 6 
 Cerebrovascular disease 2 
 Headache 2 
 Cranial nerve palsy 1 
 Neurodegenerative disease 1 
 Non-epileptic attack 1 
 Spasmus facialis 1 
MS patients   
 RRMS  18 
 SPMS 3 
 PPMS 1 
 
Abbreviations: MS = multiple sclerosis, RRMS = relapse-remitting MS, SPMS = 
secondary-progressive MS, PPMS = primary-progressive MS. 
 
 
Table 3. Demographic characteristics of MS and OND patients 
 
Cohort 1 n Age mean (range) Sex (Female:Male) 
MS 44 35.0 (17-56) 32:12 
OND 22 40.0 (17-72) 11:11 
Cohort 2    
MS 22 43.9 (24-65) 13:9 
OND 14  57.3 (30-75) 7:7 
 





6.1.3. Characterization of healthy donors 
Table 4. Demographic and genotypic characteristics of healthy donors 
 
n Age mean (range) Sex (Female:Male) 
total 221 47.1 (21-69) 160:61 
G/G 11 48.6 (33-65) 5:6 
A/G 73 48.8 (24-68) 52:21 
A/A 137 46.0 (21-69) 103:34 
 
G = protective allele at rs2104286, A = risk allele at rs2104286. Inclusion criteria 
were 20-69 years. Samples for different assays were chosen randomly and blinded 
with regard to sex, age and genotype. 
 
6.2. PBMC isolation, cryopreservation and thawing 
PBMCs were isolated by density gradient centrifugation using Lympholyte-H 
(Cedarlanes). PBMCs were cryopreserved in sterile-filtered FCS (Biochrom) + 10% 




 and stored in liquid 
nitrogen. Cyrovials were thawed in a 37 °C water bath and washed twice by drop-
wise addition of 37 °C RPMI-1640 (PAN biotech) with 10% FCS. 
 
6.3. In vitro culture 
6.3.1. Regulation of GM-CSF production 
To address the regulation of GM-CSF, sorted naïve TH cells were stimulated for 5 
days with 1 µg ml
-1
 anti-human CD3 (OKT3, Bioexcel) antibody with or without 1 
µg ml
-1
 anti-human CD28 (CD28.2, BD Pharmingen) and 10 ng ml
-1
 of one of the 
following cytokines: IL-1β, IL-6, IL-23, IL-2, IL-4, IL-7, IL-9, IL-15, IL-21 and 
TGF-β1 (all from PeproTech). Proliferation was assessed by labeling cells with 5 µM 
CFSE. Where indicated, 10 µg ml
-1
 of anti-human IL-2Rα (Basiliximab, Novartis) 
was added to the culture on day 0. To simultaneously analyze GM-CSF production 
and STAT5 phosphorylation, TH cells were cultured as described above. For 
inhibition of STAT5 phosphorylation, 2.5 µg ml
-1
 pimozide (Sigma) was added at day 
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0 and flow cytometric readouts were performed at day 5. For IL-2 restimulation of 
PBMCs obtained from healthy donors, CD4
+
 T cells were purified by MACS 
separation (Miltenyi Biotech), as suggested by the supplier. IL-2 was added in 
concentrations ranging from 0–10 ng ml
-1
 and TH cells were cultured for 4 days at 
37°C. 
 
6.3.2. Impact of regulatory T cells 
The impact of Treg cells on GM-CSF production was determined by co-culture of 
sorted naïve (labeled with CFSE, eBiosciences) and regulatory TH cells (labeled with 
CellTrace Violet, Lifetechnologies) at a 1:1 ratio for 5 days. The cells were stimulated 
with 10 ng ml
-1
 IL-2 and anti-CD3 plus anti-CD28 antibodies. Where indicated, 10 
µg ml
-1
 anti-TGF-β and anti-IL-10R (Biolegend) were added to the culture at day 0. 
 
6.4. Ex vivo restimulation of PBMCs 
The frequency of cytokine secreting cells was determined after short restimulation 
using 50 ng ml
-1
 PMA and 500 ng ml
-1
 ionomycin in the presence of a protein 
transport inhibitor (Golgiplug, BD) for 4 hours at 37 °C. 
 
6.5. Flow Cytometry 
6.5.1. Flow cytometry and cell sorting 








) from healthy donors, total 
PBMCs were stained with anti-human CD4 APC-Cy7 (RPA-T4, 1/100, BD 
Pharmingen), CD25 APC (BC96, 1/50, eBioscience), CD127 FITC (eBioRDR5, 1/50, 







 and excluded from the naïve TH cell population. 
Anti-human monoclonal antibodies used for ex vivo surface staining were 
PacificBlue-conjugated CD4 (RPA-T4, 1/200, Biolegend), Brilliant Violet™ 785-
conjugated CD8 (RPA-T8, 1/200, Biolegend), APC-conjugated CD25 (BC96, 1/50, 
eBiosciences) and PE-Cy7-conjugated CD45RA (HI100, 1/200, Biolegend). 
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6.5.2. Intracellular cytokine staining 
Intracellular cytokine staining was performed using anti-human PE-conjugated GM-
CSF (BVD2-21C11, 1/200, BD Biosciences), Alexa Fluor 488-conjugated or PE-
Cy7-conjugated IFN-γ (4S.B3, both 1/200, Biolegend or eBiosciences), APC-Cy7-
conjugated IL-17A (BL168, 1/200, Biolegend) and AlexaFluor 488-conjugated IL-4 
(8D4-8, 1/50, Biolegend). Dead cells were excluded using the LIVE/DEAD® fixable 
dead cell stain kit (Invitrogen). 
 
6.5.3. STAT5 phosphorylation and Ki-67 staining 
Respective cell populations were stimulated for 10 min at 37°C with 10 ng ml
-1
 of the 
indicated cytokine. Cells were then fixed in 1.6% PFA and permeabilzed in methanol 
on ice for 30 min. Subsequently, anti-human APC-conjugated CD4 (RPA-T4, 1/20, 
Biolegend) and PE or APC-conjugated pSTAT5 (47, both 1/20, BD Biosciences and 
C71E5, Cell signaling technology, respectively) were used for staining. Cell cycle 
analysis was performed using FITC-conjugated anti-human Ki-67 (35/Ki-67, 1/20, 
BD Biosciences). 
 
6.5.4. Acquisition and analysis 
FACS acquisition and sorting were performed on LSR-Fortessa (BD) and Aria III 
(BD), respectively. Analysis was performed using the FlowJo software (Tree star) in 
combination with Prism (GraphPad). 
 
6.6. Quantitative Real-Time PCR 
RNA was isolated with the PureLink
TM
 RNA Micro Kit and cDNA was obtained 
using SuperScript
®
 III reverse transcriptase (both Life Technologies). qPCR was then 
performed using the CSF2 and GAPDH TaqMan gene expression assay (Life 






Sorted naïve TH cells (CFSE labeled) and Treg cells (CellTrace Violet labeled) were 
placed on cover slide, pretreated with poly-l-lysine, and allowed to rest for 30 min. 10 
ng ml
-1
 IL-2Fc (Sigma) was added for 10 min before cells were washed and fixed 
with 1:1 aceton:methanol for 12h at -20 °C. IL-2Fc was then stained with APC-
conjugated anti-human IgG antibodies (G18-145, BD Biosciences). Fluorescent 




Cytokine levels of cell culture supernatants and human serum was analyzed by 
ELISA as suggested by the supplier (all Mabtech). CFS levels of MMP9 and NFL 
were determined as previously described (Khademi et al. 2013). 
 
6.9. Statistical analysis 
All statistical tests were performed using the R statistical software package or Prism 5 
(GraphPad). Differences between two groups were analyzed using a two-sided t-test, 
accounting for different variances by Welch`s correction if indicated. Non-gaussian 
distributions were compared by the nonparametric Mann-Whitney test. Analysis of 
variance (ANOVA) was used to compare more than two groups and regression 
analysis was used to test for correlations between genotype and flow cytometric data, 
controlling for age and sex. Gene-dosage effects were analyzed by linear regression, 
assuming a linear genotype-phenotype correlation. We estimated the sample size 




6.10. Healthy donor and patient samples for mass cytometry studies 
6.10.1. Recruitment of patients 
PBMC samples of MS and control patients (Table 5) were collected at the 
neurological clinics at Karolinska University Hospitals Solna and Huddinge, Sweden. 
Informed consent was collected from all participants. Mass cytometric experiments 
and initial analysis was performed blinded with regard to disease and genotype. 
 
Table 5. MS and control patient samples for mass cytometry experiments 
 
Cohort Part 1   n Age mean (range) Sex (Female:Male) 
HD 20 40 (26-55) 8:12 
OND 24 40.5 (21-74) 15:9 
PPMS 4 52.8 (43-66) 2:2 
RRMS  17 38.2 (22-55) 11:6 
SPMS 5 56 (49-60) 2:3 
Cohort Part 2      
HD 8 26.9 (20-36) 6:2 
OND 11 30.8 (20-39) 5:6 
RRMS  20 34.1 (17-55) 15:5 
 
Abbreviations: OND = other neurological disease (non-inflammatory), MS = multiple 
sclerosis, RRMS = relapse-remitting MS, PPMS = primary-progressive MS, SPMS = 
secondary-progressive. 
 
6.11. Mass cytometry 
6.11.1. Antibody conjugation and validation 
Monoclonal anti-human antibodies (Table 6) were purchased either pre-conjugated to 
heavy-metal isotopes from Fluidigm or in purified form and conjugated in house 
using the Maxpar™ X8 chelating polymer kit (Fluidigm) according to the 
manufacturer's instructions. In short, carrier protein was washed away and the 
purified antibody was partially reduced for 25 min at 37°C and lastly conjugated by 
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addition of isotope-loaded metal-chelating polymers. Following conjugation, the 
antibody protein concentration was determined by nanodrop (Thermo Scientific). 
Successful conjugation and sufficient staining signal of the antibody was then 
validated by staining cryopreserved PBMCs from various healthy donors and 
determining the specific signal above background (negative biological control 
populations or unstimulated cells).  
 
6.11.2. Live cell barcoding 
Samples were ex vivo re-activated as described above (see section 6.4). In order to 
reduce inter-sample staining variability, minimize sample-handling time and reduce 
antibody consumption, we made use of the live cell barcoding approach (Mei et al. 
2015). Therefore, isothiocyanobenzyl-EDTA (p-SCN-EDTA; Dojindo) was loaded 












In all from Trace Sciences International) as described (Zunder et al. 
2015) and subsequently used to label anti-human CD45 (Biolegend) as suggested 
(Mei et al. 2015). To further increase the number of possible samples with a unique 
barcode, pre-conjugated 
89
Y-CD45 (Fluidigm) was used as an additional barcoding 
reagent. To obtain robust barcoding results with even staining intensity on all 
samples, a 6-choose-2 scheme (or 7-choose-3) was used, resulting in 15 (or 35) 
specific combinations of heavy-metal labeled CD45 antibodies.  
PBMCs from MS and control patients were labeled with metal-tagged CD45 
antibodies after ex vivo re-activation at 37 °C for 25 min in cell staining medium 
(CSM; RPMI-1640, 4% FCS) on a rotating shaker (500 rpm). Samples were washed 
twice in CSM and combined into a single reaction vessel for further staining steps. 
 
6.11.3. Surface staining for mass cytometry 
Following live cell barcoding, the combined sample was centrifuged, supernatant was 
aspirated and cells were resuspended in 500 µL of surface antibody solution (Table 6) 
in CSM. Cells were stained for 20 min at 37 °C on a rotating shaker (500 rpm) to 
optimize chemokine receptor staining (Berhanu et al. 2003). Dead cells were excluded 
by adding 1 mL of 2.5 µM cisplatin (Sigma) in PBS at the end of the staining period 
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and incubating for 2 min on ice (Fienberg et al. 2012). Afterwards, the sample was 
once washed once with PBS/BSA (PBS, 0.5% bovine serum albumin (BSA; Sigma). 
 
Table 6. Antibodies and other staining-reagents used for mass cytometry. 
Isotope Metal Antigen Clone Supplier Category 
89 Y BC89 HI30 Fluidigm barcoding 
104 Pd BC104 HI30 Biolegend barcoding 
105 Pd BC105 HI30 Biolegend barcoding 
106 Pd BC106 HI30 Biolegend barcoding 
108 Pd BC108 HI30 Biolegend barcoding 
110 Pd BC110 HI30 Biolegend barcoding 
115 In BC115 HI30 Biolegend barcoding 
141 Pr CCR6 G034E3 Fluidigm surface 
142 Nd IL-4 MP4-25D2 Fluidigm ICS 
143 Nd CCR2 K036C2 Biolegend surface 
144 Nd CD57 HCD57 Biolegend surface 
145 Nd CD4/CD4 RPA-T4/OKT4 Fluidigm/Biolegend surface 
146 Nd CD8a RPA-T8/SK1 Fluidigm surface 
147 Sm CD56 NCAM16.2 BD surface 
148 Nd IL-17A BL168 Fluidigm ICS 
149 Sm IL-3 BVD8-3G11 Biolegend ICS 
150 Nd IL-22 22URTI Fluidigm ICS 
151 Eu CD103 Ber-ACT8 Fluidigm surface 
152 Sm TCRgd 11F2 Fluidigm surface 
153 Eu CD25 M-A251 Biolegend surface 
154 Sm IL-6 MQ2-13A5 Biolegend ICS 
155 Gd IL-9 MH9A4  Biolegend ICS 
156 Gd IL-13 JES10-5A2 Biolegend ICS 
158 Gd CCR4 205410 Fluidigm surface 
159 Tb GM-CSF BVD2-21C11 Fluidigm ICS 
160 Gd CD69 FN50 Biolegend surface 
161 Dy CD20 2H7 Biolegend surface 
162 Dy CD27 O323 Biolegend surface 
163 Dy CD14 M5E2 Biolegend surface 
164 Dy CD45RO UCHL1 Fluidigm surface 
165 Ho IFN-g B27 Fluidigm ICS 
166 Er IL-10 JES3-9D7 Fluidigm ICS 
167 Er CCR7 G043H7 Fluidigm surface 
168 Er TNF-a MAb11 Biolegend ICS 
169 Tm CD45RA HI100 Fluidigm surface 
170 Er CD3 UCHT-1 Fluidigm surface 
171 Yb CXCR5 51505 Fluidigm surface 
172 Yb IL-21 3A3-N2 Fluidigm ICS 
173 Yb CXCR4 12G5 Fluidigm surface 
174 Yb CD28 CD28.2 Biolegend surface 
175 Lu PD-1 EH12.2H7 Fluidigm surface 
176 Yb IL-2 MQ1-17H12 Biolegend ICS 
191 Ir DNA1 Fluidigm other 
193 Ir DNA2 Fluidigm other 
195 Pt Dead Sigma other 
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6.11.4. Intracellular cytokine staining for mass cytometry 
Surface-stained cells were fixed by resuspending them in 1.6% paraformaldehyde 
(PFA; Electron Microscopy Sciences) for 25 min at 4 °C on a rotary shaker (500 
rpm). Afterwards, the sample was washed twice with permeabilization buffer (PBS,  
0.5% saponin, 2% BSA, 0.01% sodium azide, all Sigma), the supernatant was 
aspirated and the sample was resuspended in 500 µL of intracellular antibody mixture 
(Table 6) in permeabilization buffer for 1 h at 4 °C on a rotary shaker (500 rpm). The 
sample was washed with permeabilization buffer, the supernatant was aspirated and 
the cells were resuspended in 500 µL of iridium intercalator solution (Fluidigm) over 
night. Next, the sample was washed twice with PBS/BSA, once with ddH2O, 




 and filtered through a cell strainer cap (Falcon) 
before acquisition. 
 
6.11.5. Acquisition on CyTOF2 mass cytometer and bead normalization 
Samples were acquired on a CyTOF2 mass cytometer (DVS Sciences/Fluidigm). 
Quality control and tuning processes were performed on a daily basis before 
acquisition. Data from different days was normalized by adding 5-element beads 
(Fluidigm) to the sample immediately before acquisition and using the matlab-based 
normalization software as described previously (Finck et al. 2013). Only events with 
event length between 10 and 100 were exported. 
 
6.12. Algorithm-guided data analysis 
6.12.1. Data pre-processing 





Ir) and live cells (
195
Pt) using FlowJo (Treestar). Next, cells 
were assigned to their initial samples using debarcoding software (Zunder et al. 
2015). Bead-normalized files were then transformed using an inverse hyperbolic sine 
(arcsinh) function with a cofactor of 5 (Bendall et al. 2011) using the R environment 
(R Development Core Team 2008). In order to improve comparability of samples 
acquired on different days and to equalize the contribution of each marker in 
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subsequent automated data analysis steps, we performed a percentile normalization 





 percentile for low expressed cytokines) of the combined (barcoded) sample. 
This preserves inter-sample variability in maximum expression values which might be 
biologically relevant. 
 
6.12.2. FlowSOM clustering 
Following pre-processing, all samples from all cohorts were down sampled to a 
maximum of 100’000 cells/sample, combined into one file and subjected to the 
FlowSOM clustering algorithm in order to identify meaningful immunological 
populations (see section 1.6.5.5). We choose FlowSOM over other clustering options 
(see section 1.6.5) for several reasons: (1) in our hands it identified clusters which 
efficiently represented immune populations that we expected to be present based on 
prior biological knowledge, (2) its availability within the R environment which 
enabled us to perform large parts of the analysis in a streamlined way, (3) it was able 
to perform clusterings within a few minutes on a standard desktop computer enabling 
us to run it multiple times and thus compare the influence of different input 
parameters, especially the k-value used in the meta-clustering step. FlowSOM was run 
on the combined sample to facilitate the identification of small populations which 
could be overlooked when clustering is performed on each single sample. After the 
initial clustering step, resulting nodes were subjected to meta-clustering. The 
respective k-value was chosen manually and in a way so that we were still able to 
identify all populations which were expected to be present, based on general 
biological knowledge. To make use of the whole, high-dimensional data, all analyzed 
markers were used for this clustering analysis. However, we adjusted the weighing of 
the input markers according to our scientific question, e.g. for the identification of 
PBMC populations we increased the scale for all lineage markers from 0-1 to 0-2. 
Likewise, for the analysis of cytokine co-production by different immune subsets, we 




6.12.3. t-SNE dimensionality reduction 
In order to visualize the high-dimensional data and to perform a quality control of the 
FlowSOM clustering we additionally performed t-SNE dimensionality reduction (see 
section 1.6.5.2), creating a two-dimensional plot of all cells,  and compared whether 
the visually distinct populations obtained from t-SNE correspond to the populations 
defined by the FlowSOM algorithm. In case we performed weighing for the clustering 
algorithm, the same scales were also used for t-SNE visualization. Again, the 
combined sample was used and further down sampled to 20’000 cells to avoid 
overcrowding. Two-dimensional t-SNE was then run using the Rtsne package in R 
with a predefined random seed to ensure reproducibility. 
Another analysis approach of using a categorical, one-dimensional variant of the t-
SNE algorithm was recently shown to be helpful in the precise analysis of immune 
subpopulations (Cheng et al. 2015). We employed to same principle by categorizing 
our panel into lineage, differentiation and activation, trafficking and cytokine antigens 
and using these categorical t-SNE dimensions to further explore immune 
subpopulations. When using these categorized sets of input markers, no weighing was 
necessary. 
 
6.12.4. Statistical analysis of mass cytometry experiments 
In order to compare the frequency of algorithm-defined populations between the 
different groups of MS and control patients, we made use of the non-parametric 
Mann-Whitney-Wilcoxon test. All pairwise tests were calculated between OND and 
the respective population of MS patients. Multiple comparisons correction for all 
populations analyzed in the respective experiment was performed with the 
Bonferroni-Hochberg correction. The level of significance with the respective false-
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